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ABSTRACT 
 
Background: Healthcare costs for the treatment of mCRPC continue to rise year on year. 
However, with the advent of targeted Nuclear medicine and continued treatment with standard 
chemotherapy regimen for the treatment of mCRPC the costs are still not known.  
Aim: We sought to compare the costs of treating mCRPC with standard chemotherapy regimen 
versus targeted Nuclear Medicine. 
Methods: We conducted a retrospective and prospective inferential study on patients, diagnosed 
with mCRPC, aged >18 years at Steve Biko Academic Hospital (SBAH), Pretoria and Inkosi 
Albert Luthuli Central Hospital (IALCH) in Durban, South Africa. The patients were referred to 
the treatment centres between the periods 1 January 2017 and 24 November 2019. We employed 
the International Classification of Diseases, 10th Revision Code system to identify mCRPC patients 
and match them with their Medical Record Number using MediTechTM computer Software 
program at IALCH, and a thorough patient file audit at SBAH was used to identify patients who 
were treated for mCRPC in this hospital during the study period. Treatment, Imaging, Screening, 
Out-patient and hospitalisation costs were extracted from the MediTechTM system using the 
Activity Based Costing Model and costs were compared to the costs derived from the patient files 
for the Nuclear Medicine patients. 
Results: A total of 60 patients (n=49, Chemotherapy Cohort, and n=11, Nuclear Medicine Cohort) 
with mCRPC, Mean ages at diagnosis 66 and 61 years respectively. The most common 
chemotherapy used were Bicalutamide, Goserelin and Docetaxel, compared to one comparator Lu-
PSMA-Radioligand. The total healthcare costs for Chemotherapy were estimated at 500 000USD 
($), whilst the costs for Lu-PSMA-Radioligand averaged 184 000USD ($). Imaging costs for 
chemotherapy were 37% higher than Lu-PSMA costs, in- hospital and out-patient costs accounted 
for 88% of the total healthcare costs. 
2 
 
Conclusions: For the treatment of metastatic resistant Prostate Cancer, patients treated with 
Chemotherapy regimen incur more cost for chemotherapy (43%) and imaging (37%) than patients 
treated with targeted nuclear medicine. Chemotherapy treated patients experience more in-patient 
and out-patient days compared to patients treated with targeted nuclear medicine. There are 
significantly more chemotherapy cycles and drug combinations that contribute to the higher 
chemotherapy costs.  
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CHAPTER 1: Introduction and Literature Review 
 
1.1 Cancer 
 
The World Health Organization (WHO) defines cancer as a large and diverse group of deadly 
disease, which is characterised by the abnormal multiplication and growth of the body’s own cells 
(WHO, 2018). Cancer is expected to rank as the leading cause of death and the single most 
important barrier to increasing life expectancy in every country of the world in the 21st century 
(Bray et al., 2018). This disease constitutes a major public health burden globally. An increasing 
trend has been observed over the past 20 years in the new cases and deaths from different cancer 
worldwide, especially in low-and middle-income countries (LMICs), owing to varying lifestyles, 
behavioural patterns and geographic and environmental factors (Adeloye et al., 2016).  
 
Carcinogenesis is recognised as a multistep process in which a series of genetic alterations occurs 
within a cell, and through processes of promotion and progression, leads to malignancy (Rubin & 
Williams, 2001).  It is also reported that cancer cells do not respond to the normal processes that 
regulate cell growth, proliferation, and survival, and they cannot carry out the physiological 
functions of their normal differentiated (mature) counterparts (Koda-Kimble et al., 2009).  
 
Cancer can be classified as benign or malignant. Benign cancers are usually localised to the organs 
or sites where they occur, and they are generally easier to manage and are less fatal. However, 
malignant cancers have the ability to migrate beyond their usual boundaries and can cause death 
(WHO “2018”). Malignant cancer cells have been observed to exhibit self-sufficiency in growth 
signals. They are also due to insensitivity to apoptotic stimuli such as the apoptotic protease 
activity factor-1 (APAF-1), as was reported by Sun & Peng (2009). The apoptotic protease activity 
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factor-1 usually binds to cysteine aspartate protease enzymes 9 (caspase-9), which activates cell 
death. Thereafter, caspase-3 is believed to play a critical role in execution of cell death (Sun & 
Peng, 2009). As a result of weakened inhibitory signalling pathways in aberrant cells, proliferation 
becomes uncontrollable. Furthermore, a sustained pathological angiogenesis causes cancer growth 
by enabling capillary blood supply, with oxygen and nutrients, to the tumour area (Vassilev & 
DePamphilis, 2017).  This brings about unsustainable tumour growth and metastasis to distant sites 
utilising unusual metabolic pathways to generate energy needed by the cells in order to survive 
and to thrive (Warburg, 1931).   
 
1.1.1 Cancer Aetiology 
 
The WHO and numerous other researchers reported that there are at least five groups of factors 
that are considered as the main causes of cancer; environmental factors (i.e., “modifiable risk 
factors”), genetic predispositions (WHO, Fact Sheet No: 297, 2015), some medical therapies (e.g. 
cytotoxic chemotherapy, immunosuppressive therapy or radiation therapy, (Koda–Kimble et al., 
2009), chronic inflammation and “cancer stem cells” (CSC). The latter was espoused recently by 
Tomasetti & Vogelstein (2015). Recently, Vassilev and colleagues (2017) reported that some 
tissues give rise to human cancers millions of times more often than other tissue types either 
through random mutations (intrinsic factors) or due to exposure to viruses, chemical carcinogens 
and radiation (extrinsic factors), during a person’s lifetime (Vassilev et al., 2017). 
 
1.1.1.1 Environmental Factors 
Youlden and colleagues (2008) have cited environmental factors such as smoke, asbestos, air 
pollution, coal heating, combustible material, tobacco use, alcohol use, infection (bacterial and 
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viral) ionisation irradiation and outdoor particulate matter to be associated with a variety of cancers 
which include lung and liver cancers (Youlden et al., 2008). 
 
Key (1994), described cigarette smoking as a major cause of lung cancer. Dietary factors such as 
high intake of meat or animal fat have been associated with colorectal and prostate cancers. Other 
than diet, sedentary lifestyles have also been linked to many cancers including the prostate and 
liver cancers. Torre and colleagues (2016), listed occupational exposure such as asbestos and air 
pollution amongst the causes of lung cancer. Importantly, smoking has been widely accepted as 
one of the main causes of lung cancer and colorectal cancer. 
 
Predisposition to bacteria and viruses such as Helicobacter pylori and human papillomavirus 
(HPV) cause stomach and ovarian cancer, respectively. Viruses such as Hepatitis B and C 
predispose individuals to liver cancer (Torre et al., 2016). 
 
1.1.1.2 Genetic Predisposition 
Over recent decades, a number of genes that cause predisposition to cancer have been identified 
(Turnbull & Hodgson, 2005). These authors further have also reported that in the majority of 
families, the increased incidence of cancers is due to multifactorial aetiology with a number of 
lower penetrance cancer predisposition genes interacting with environmental factors.  
 
Genetic mutations due to dietary habits and certain medications (e.g. hormone replacement 
therapy) have been found to be associated with a variety of cancer (Youlden et al., 2008). In a 
study conducted by Torre et al. (2015), genetic makeup, being overweight/obesity, growth, 
ethnicity, and ageing population and changing reproductive patterns associated with urbanisation 
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and economic development were reported to be associated with certain cancers such as breast and 
ovarian and prostate cancers. 
 
Ethnicity, such as being black or African American, has been associated with predisposition to 
prostate cancer (Key, 1994). Turnbull & Hodgson, (2005) have also reported that alterations in 
germ line cancer predisposition genes, namely; tumour suppressor genes (TSG) and oncogenes 
(OG), have been found to be associated with inherited cancer predisposition. 
 
It was reported by Koda-Kimble and colleagues (2009) that damage to cellular DNA can result in 
mutations that lead to the development of oncogenes and loss or inactivation of tumour suppressor 
genes. These authors further stated that oncogenes arise from normal genes called proto – 
oncogenes through genetic alterations such as chromosomal translocations, deletions, insertions 
and point mutations. It is their over activity or presence in certain forms that may lead to the 
development of cancer (Koda-Kimble et al., 2009).  
 
Rubin and Williams (2001) also reported that intrinsic cellular oncogenes, growth suppressor 
genes and the dysregulation of steps that control cell cycle, cell proliferation, and differentiation 
through gene expression play interactive roles that transform normal cells into a premalignant state 
and ultimately into malignancy.  
 
The tumour suppressor genes have been defined by Koda–Kimble et al.,(2009) as normal genes 
that encode for proteins that suppress inappropriate cell division or growth. It is reported by these 
authors that gene losses or mutations of these genes can cause these proteins to become inactivated, 
eliminating the normal inhibition of cell division. It is therefore believed that multiple genetic 
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mutations, including activation of oncogenes and loss or inactivation of tumour suppressor genes 
within a cell, are necessary for malignant transformation (Koda-Kimble et al., 2009). 
 
Injury to cells and microbial infection initiate a cascade of inflammatory processes. However, 
inadequate anti-inflammatory response or repeated infections may predispose human cells to 
chronic inflammation (Medzhitov, 2010). The events that lead to chronic inflammation are 
discussed below. 
 
1.1.1.3 Chronic Inflammation 
It is estimated that the underlying infections and inflammatory responses cause 15-20% of all 
deaths from cancer worldwide (Mantovani et al., 2008). Therefore, numerous studies have been 
conducted dating back to the 19th century to elucidate the link between cancer and chronic 
inflammation. Observations of infections with a number of microorganisms such as Helicobacter. 
pylori, Epstein Bar virus (EBV) and Schistosoma species, to name a few, have been associated 
with various cancer types and there is a strong suggestion that chronic inflammation is involved in 
tumour initiation, promotion and progression (Lin & Karin, 2007). Immune deregulation and 
autoimmunity have also been found to precede tumour development (Grivennikov et al., 2010). 
 
Medzhitov (2010) describes the inflammatory process as a pathway that consists of inducers, 
sensors, mediators and target tissues. An infection or injury to the cell initiates the inflammatory 
response, and this induction is detected by the sensors such as Toll-like receptors (TLRs) expressed 
on tissue, resident macrophages, dendritic cells and mast cells (Medzhitov, 2010). The receptors 
recognise pathogen-associated molecular patterns (PAMP), such as cell wall components and 
nucleic acids (Lin & Karin, 2007). Microbial detection is achieved through germ line-encoded 
pattern-recognition receptors (PRRs). These receptors survey both the intracellular and 
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extracellular space for microbial determinants that serve as indicators of infection and induce the 
innate immune responses to protect from infectious threats (Medzhitov 2010).  Lin and colleague 
further stated that PPRs include TLRs, nucleotide-binding oligomerization domain like (NOD-
like) receptors, C-type lectin receptors (CLRs) and triggering receptors expressed on myeloid cells 
(TREMs) (Lin & Karin, 2007). The interaction between PAMPs and PPRs results in the activation 
of inflammatory cells and initiation of host responses whose major purpose is to eliminate and kill 
invading organisms. However, inadequate pathogen eradication, prolonged inflammatory 
signalling, and defects in anti-inflammatory mechanisms can all lead to chronic inflammation and 
benefit tumour development (Lin & Karin, 2010). 
 
In the main, the production of mediators such as cytokines, chemokines (CCL2 & CXCL8), 
bioactive amines, eicosanoids and products of proteolytic cascades such as bradykinin, as well as 
prostaglandins have been associated with cancer. Notably,   Interleukin-1 (IL-1), Interleukin-6 (IL-
6), and Interleukin-17 (IL-17) are potent inflammatory cytokines that have been linked with 
tumourigenesis (Medzhitov, 2010). In particular, IL-6 promotes inflammation, tissue damage, 
compensatory cell proliferation and ultimately formation of tumour (Grivennikov et al., 2010). It 
has also been observed that the downstream mediators us as STAT3 and NF-κB, activate genes 
that control cell survival, proliferation, angiogenesis and invasion. More importantly, Calcinotto 
and colleagues (2018) have recently demonstrated that Interleukin-23 (IL-23) is the inflammatory 
cytokine that play a major role in the development of resistant prostate cancer (Calcinotto et al., 
2018).  
 
1.1.1.4 Cancer Stem Cell 
In a study by Tomasetti and Vogelstein (2015), it was reported that many genomic changes occur 
simply by chance during normal deoxyribonucleic acid (DNA) replication, rather than as a result 
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of carcinogenic factors. This is because most cells in tissues are partially or fully differentiated 
cells and are typically short-lived, and unlikely to initiate a tumour. Therefore, cancer results from 
genetic mutations that are either inherited or acquired through DNA replication errors and 
environmental insults (Vassilev et al., 2017). However, it can also be as a result of stem cells that 
retain their ability to proliferate repeatedly (Vassilev et al., 2017).    
 
The stem cells are the only cells that can self-renew and are responsible for the development and 
maintenance of the tissue’s architecture. Therefore, they have the capacity to initiate the tumour 
(Tomasetti & Vogelstein, 2015). It was also stated by Tomasetti & Vogelstein (2015) that three 
mutations occur every time a normal human cell divides, as a result an inference was made to 
conclude that the root causes of the correlation between stem cell division and cancer incidences 
were the driver gene mutations that randomly result from these cell divisions. 
 
1.1.2 Epidemiology and Global Burden of Cancer 
 
Globocan (2018), data indicate that cancer incidences and mortality are rapidly growing 
worldwide, and the reasons are complex, with aging, growth population as well as changes in the 
prevalence and distribution of the main risk factors for cancer, several of which are associated with 
socio-economic development, being at the centre of this epidemic (Bray et al., 2018). In 2012 
alone, there were 14.1 million new cases and 8.2 million deaths from cancer globally, and this 
burden is expected to rise with over 75 million prevalent cases, 27 million incident cases, and 17 
million cancer deaths expected globally by 2030 (Adeloye et al., 2016). Recently, Fitzmaurice 
(2018) reported that 7.2 million cancer cases were reported in 2016 worldwide and 8.9 million 
deaths. Most new cases of cancer are now found in Africa and LMICs, increasing from 15% in 
1970, to 56% in 2008, and projected to reach about 70% by 2030 (Adeloye et al., 2016). 
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Cancer constitutes an enormous burden on society across the world. Recent studies have reported 
that the prevalence of cancer is increasing mainly because of the growth and rapid aging of the 
global populations (Torre et al., 2015; Martins, 2016). Smoking, obesity, physical inactivity, and 
changing reproductive patterns, urbanisation and economic development have also been associated 
with high incidences of cancer in the western developed world (Torre et al., 2015). 
 
1.1.2.1  Cancer Incidences Globally 
Globally, cancer is the second leading cause of death and accounted for 8.8 million deaths in 2015 
(WHO, 2017). Lung, prostate, colorectal, stomach and liver cancers are the most common types 
of cancer in men, while breast, colorectal, lung, cervix and stomach cancers are the most common 
among women (WHO, 2017). Over the years, the burden has shifted towards the less developed 
countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide 
(Torre et al., 2015). It is reported that lung cancer is the leading cause of cancer death among males 
in both more and less developed countries, and has surpassed breast cancer as the leading cause of 
cancer death among females in more developed countries (Torre et al., 2015).  
 
1.2.1.2  Cancer Incidences in sub-Saharan Africa 
Lorenzino and colleagues (2018), recently reported that there were 626 399 new cancer cases in 
sub-Saharan Africa in 2012 (Lorenzino et al., 2018). This represents 4.4% of the 14.1 million new 
cancer cases globally.  This is almost the same number (i.e., 667 000) of cancer cases that was 
estimated to have occurred in 2008 for the whole of Africa. Meaning, the sub-Saharan region 
accounts for the bulk of cases and deaths due to cancer in Africa.  
 
11 
 
1.2.1.3  Cancer Incidences in South Africa 
South Africa, in particular, has been ranked 50th on the World Cancer Research Fund’s list of 
countries with the highest cancer prevalence rates (CANSA, 2018). Furthermore, the South 
African Medical Research Council reported that in 2012 cancer was the fifth leading cause of death 
in South Africa, causing 8.7% of all reported deaths (CANSA, 2018). However, prevalence 
patterns of cancer in South Africa are similar to global trends although local data is insufficient 
due to under-reporting (Singh et al., 2015). For example, prostate cancer is also the leading organ-
specific cancer diagnosed amongst South African men followed by lung, oesophagus, 
colon/rectum and bladder cancer. Amongst South African women too, breast cancer is the most 
prevalent cancer, followed by cervical, uterus, colorectal and oesophageal cancers (CANSA, 
2018).  
 
In South Africa, 6807 cases of prostate cancer, 1839 of colorectal and 1743 of lung cancer were 
reported in 2012 in South African men, accounting for 18.45%, 4.98% and 4.72% respectively.  
8203 cases of breast cancer, 5785 cervical cancer cases and 1558 colorectal cases were reported 
in South African women, accounting for 21.79%, 15.37% and 4.14% of cancer cases respectively 
(CANSA, 2018). 
 
1.2 Prostate Cancer (PCa) 
 
Underwood & Cross (2009) defined prostate cancer as an adenocarcinoma that occurs in men 
usually above 50 years of age. It is reported by the authors that the tumour is rare below the age of 
50 years of age, with the peak incidence between the ages of 65 – 75 years (Underwood & Cross, 
2009).  The prostate is a gland in the male reproductive system, located below the man’s bladder 
and is responsible for the secretion of the seminal fluid (Shalini et al., 2011).  This fluid acts as a 
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nutrient rich transport medium for sperm, produced by the testes. The hormone testosterone 
influences the prostate. The prostate is about the size of a walnut, estimated to weigh 20g to 25g 
as reported by De Vita et al., 2015).  The authors further state that the seminal fluid is rich in 
Prostate Specific Antigen (PSA). It is reported by the same, that the prostate is located deep in the 
pelvis between the bladder and the external urinary sphincter, anterior to the rectum below the 
pubis. It is because of this location, which is a critical anatomic juncture, that it is believed that 
cancers of the prostate and the treatment thereof, place urinary, sexual and bowel function at risk 
(De Vita, et al., 2015) 
 
Rubin & Williams (2001) reported that the normal anatomy of the prostate is considered to be 
made up of anatomic zones, namely, the peripheral zone (makes up 70% of the glandular tissues 
of the prostate gland), the central zone (surrounds the ejaculatory ducts), and the transition zone 
(surrounds the urethra). In addition to these zones, there is a non-glandular anterior fibromuscular 
stroma (Rubin & Williams, 2001; De Vita, et al., 2015). 
 
The peripheral zone has been reported to be the region most prone to the development of 
carcinomas, whilst very few cancers originate from the central zone and only 15% of cancers 
originate in the transition zone (De Vita, et al., 2015).  
 
 In patients with cancer, the prostate gland enlarges and squeezes the urethra, and may slow or stop 
normal urine flow. Prostate cancer is a hormone-dependent and epithelial-derived tumour, which 
result from uncontrolled growth of genetically unstable transformed cells (Shalini et al., 2011).  
High androgen receptor (AR) level in primary tumour predicts increased prostate cancer-specific 
mortality. However, the mechanisms that regulate AR function in prostate cancer are poorly known 
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(Shalini et al., 2011). It has been reported that infection with sexually transmitted infections 
chlamydia, gonorrhoea, or syphilis increases the risk of PCa (Mustafa, et al., 2016). 
 
1.2.1 Epidemiology of Prostate Cancer 
 
In a recent study conducted by Dong and colleagues, it was reported that approximately 160 000 
new diagnosis of PCa and over 29 000 deaths were estimated to occur in the United States in 2018. 
The authors also reported that in 2012, 400 000 European men were newly diagnosed with PCa 
out of a global 1.1 million new cases. (Dong, et al., 2018). Wen et al. (2019) also reported that of 
men diagnosed with PCa, 6 in 10 are men aged 65 years or over. It was also stated by Wen and 
colleagues  that the median  age at the time of PC diagnosis is 66 years, with the rates of death 
highest among men aged 75 -84 years.  
 
The incidences of PCa vary across the globe (Le Roux et al., 2015).  Prostate cancer is the second 
most common cancer and the fifth leading cause of cancer-associated mortality among men 
worldwide (Ilic et al., 2018).  Over 1.3 million new cases and 359 000 deaths were projected for 
PCa in 2018 worldwide (Bray, et al., 2018). In South Africa, PCa is the most frequently diagnosed 
cancer in men, and is second only to lung cancer in terms of mortality (Dewar et al., 2018).  
 
Prostate cancer is the leading cause of cancer deaths among 46 countries particularly Sub-Saharan 
Africa and the Caribbean, and the mortality rates are elevated in the Sub-Saharan Africa regions 
such as Benin, South Africa, Zambia and Zimbabwe as well as the Caribbean (Barbados, Jamaica 
and Haiti (Bray, et al., 2018). Trinidad and Tobago studies have also reported prostate cancer as 
the most common cancer in men (Persuad et al., 2018). In the United Kingdom and the United 
States of America, black men of different backgrounds are at a higher risk of developing PCa 
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(Machironi et al., 2018).  Adeloye (2016) and Bray and colleagues (2018) have reported that the 
mortality rates from PCa are generally higher in predominantly black African populations 
compared to other races. 
 
In north America, black men present with more aggressive and advanced disease than men of other 
ethnic groups with a worse prognosis (Le Roux, et al., 2015). Men with west African ancestry 
living elsewhere, such as south America, the United Kingdom and the Caribbean, have similarly 
high rates of prostate cancer. However, studies focused on South Africa have uniformly found PCa 
to be more common in white than black South Africans (Dewar et al., 2018). However, Le Roux 
and colleagues (2015) reported that the majority of PCa patients in public South African hospitals 
were predominantly black and presented with advanced or metastatic disease. 
 
This disparity is also noted in other studies and has been attributed to under-diagnosing of PCa in 
the African black population (Dewar et al., 2018). Lower PCa incidence and mortality rates were 
observed in northern Africa at 10.6 and 7.0 per 100 000 compared to the average rates in Sub- 
Saharan Africa (SSA) with 34.3 and 22.1 per 100 000, respectively, and these were attributed to 
relatively higher poverty levels, dietary differences, genetic differences and the presence of 
infectious diseases in sub-Saharan Africa (Adeloye et al., 2016). 
 
Cancer Association of South Africa (CANSA) cites the lack of adequate information supplied to 
the Cancer registry by the pathological laboratories for all patients tested to be a hurdle in the 
availability of up to date PCa data in South Africa (CANSA, 2018).  
 
There is substantial geographic variation in the incidences of PCa. Almost 75% of the registered 
cases occur in developed regions like Australia, New Zealand, United States and Europe, which is 
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likely due to the widespread use of prostate specific antigen (PSA) screening test as well as biopsy 
in these regions (Saraf, 2013). Screening for PCa remains controversial because of limitations in 
randomised trials including contamination and under-representation of black men (Ilic et al., 
2018). The United States Preventative Services Task force recommended an individualised 
screening approach among men aged 55-69 based on patient-clinician discussion (Persuad, et al., 
2018). Screening for prostate cancer with PSA aims to detect prostate cancer at an early stage, to 
enhance the success rates curative treatment and to reduce the overall and disease-specific 
mortality (Ilic et al., 2018). Screening by a combination of digital rectal examination (DRE) and 
PSA testing is recommended by many experts since a proportion of clinically significant cancers 
may be potentially missed by utilising PSA alone (Ilic et al., 2018). 
 
1.2.2  Aetiology of Prostate Cancer 
 
Many authors have reported that the aetiology of prostate cancer is unknown. However, it has been 
widely reported also that many cancers of the prostate are hormone (Androgen) dependent 
(Underwood & Cross, 2009). Dong and colleagues (2018) stated that the androgen receptor (AR) 
is a key regulator of normal prostate function as well as cancer development. Rubin & Williams 
(2001) have also reported that men castrated early in life rarely develop PCa, implicating the male 
hormone testosterone as a requirement for PCa. 
 
In a study conducted by Jang et al. (2016), it was stated that in Castrate Resistant Prostate Cancer 
(CRPC), it has been proven and widely accepted that an androgen receptor signalling activity is 
persistent  and that residual  androgens continue to drive AR signalling activity ( Jang, et al., 2016). 
The authors further stated that molecular studies have shown that tumour progression in CRPC is 
related to AR-associated signalling mechanisms which include AR overexpression and 
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amplification, AR mutations, and increased AR ligand expression in the surrounding stroma. In 
another study by Gravis (2018), constitutive activation of the AR, alternative splicing events, and 
proliferation of prostate tumour cells independent of androgens have been found to contribute to  
castration resistance (Gravis, 2019). 
 
1.2.3 Risk Factors of Prostate Cancer 
 
The risk of PCa increases with age, family history of the disease, genetics, dietary fat and/or meat 
intake and a history of sexually transmitted disease (Shalini et al., 2011; Gul et al., 2016). It is 
reported that lower Vitamin D blood levels may increase the risk of PCa development (Shalini et 
al., 2011). In comparison with both breast and colon cancer, which are usually the two cancers 
with well-recognised familial tendencies, prostate cancer has been reported to have a higher degree 
of heritability (Shalini et al., 2011).  
 
1.2.3.1  Age 
De Vita et al. (2015) have reported that clinically detected PCa is rare before the age of 40, but 
incidence increases with age and continues to rise through the ninth decade of life. This has been 
noted by Gul et al. (2016) who stated that more notably, the risk of PCa has been found to be 
greatest for men over 65, and very rarely occurs under the age of 40 years. However, it has been 
reported that most men diagnosed with PCa do not die from it (Rubin & Williams, 2001). Mustafa 
et al. (2016) also reported that autopsy studies of Chinese, German, Israeli, Jamaican, Swedish and 
Ugandan men who died of other causes have found PCa in 30% of men in their 50s, and 80% of 
men in their 70s. 
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1.2.3.2  Genetic Susceptibility & Family History 
 
De Vita et al. (2015) reported that men with a first degree relative with PCa have a two to three 
fold increased risk of developing PCa, and those with two or more first degree relatives affected 
have a five to eleven fold increased risk compared to the general population.  
 
It has been stated by Rubin & Williams (2001) that the incidence of PCA among blacks in the US 
is nearly two fold that of whites and forty times that of native Japanese males. However, it has 
been further stated  by Rubin and Williams (2001) that these major differences may be a result of 
diet or other lifestyle changes because the risk increases among Asian men who adopt a western 
lifestyle. 
 
1.2.4 Clinical Manifestations of Prostatic Cancer 
 
Underwood & Cross (2009) reported that diseases of the prostate are common causes of urinary 
problems in men, characterised by the enlargement of the organ resulting in compression of the 
intraprostatic portion of the urethra and this leads to impaired urine flow, an increased risk of 
urinary infections and in some cases acute retention off urine requiring urgent relief  
catheterisation. In studies conducted by Slater (2019) it was reported that PCa symptoms do not 
usually manifest in the early stages of the disease, but later when the disease has progressed. These 
include abdominal pain, anaemia, bloody semen, haematuria, fatigue, incontinence, leg 
inflammation, spinal compression and weight loss (Slater, 2019). Advanced PCa causes additional 
symptoms due to metastases as reported by Mustafa and colleagues (2016).  These include bone 
pain, often in the vertebrae, pelvic or ribs as well as the proximal spread to the femur (Mustafa et 
al., 2016). 
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Pathological fractures and peripheral lymphadenopathy due to metastatic carcinoma are 
occasionally other initial clinical presentations, as well as rectal examination revealing a hard, 
craggy prostate (Underwood & Cross, 2009). Clinically, there are five clinical subtypes of prostate 
cancer based on location of metastatic sites. Namely; (1) locally progressing tumours with no 
metastasis, (2) rising prostate specific antigen (PSA) with no detectable metastasis, (3) nodal 
spread with no visceral disease, (4) detectable bone metastasis, and (5) visceral disease with liver 
and lung metastasis (Scher et al., 2008). However, this clinical classification does not define 
biology of the disease, and it fails to reflect the latest imaging technology used for the diagnosis 
and screening technology for prostate cancer (Cheng et al., 2012).  
 
1.2.5 PCa Screening and Diagnosis  
 
Standardised screening tests can help identify diseases in asymptomatic individuals (screening) or 
help diagnose a disease in symptomatic individuals (early detection), Koda-Kimble, et al., (2009). 
The authors further list four basic requirements that should be met by screening tests namely, (1) 
There must be good evidence that the test is effective in reducing morbidity or mortality, for 
example, effective treatment must be available for the screened disease, (2) the benefits of the test 
must outweigh its risks, (3) the costs of the test should be in balance with its presumed benefits, 
and (4) the test should be practical and feasible within the existing health care setting (Koda -
Kimble et al.,  2009).  
 
The goal of cancer screening for early detection of PCa is to prevent death and suffering from the 
disease through early therapeutic intervention (De Vita et al., 2015). The Prostate Cancer 
Foundation of South Africa, advocates for a final decision about treatment to be made by the fully 
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informed patient, assisted by his wife and / or other family members who should be given access 
to complete and unbiased information from all the experts who may be involved in his treatment 
(Segone, et al., 2013). Underwood & Cross (2009) reported that there are four common ways to 
diagnose localised or non-metastatic PCa, namely (1) Digital Rectal Examination (DRE), (2) 
Serum Prostate Specific Antigen (PSA), (3) Trans-rectal Ultrasonography (TRUS), and (4) Needle 
Biopsy. 
 
It was recently reported by Segone and colleagues (2013) that asymptomatic PCa can be diagnosed 
early by routine cancer screening. This screening process involves (PSA) blood test, a DRE in men 
above the age of 50, or 45 if there is a family history of PCa, biopsy staging and grading of PCa. 
 
1.2.5.1  Prostate Specific Antigen (PSA) 
PSA is a protein that is secreted by prostate cells. This test gives better short term outcomes after 
diagnosis (Shalini et al., 2011). PSA is defined as a 28kDa protein of a Kallikrein family, a group 
of serine proteases whose genes are found in the chromosome 19q13 (De Vita, et al., 2015). It is 
produced by normal and malignant epithelium and secreted into the seminal fluid.  It is said that 
PSA is not only involved in screening for early detection of PCa, but also in detection of 
recurrences and disease progression (Walker & Edwards, 2003). The increased levels of PSA in 
the blood stream are indicative of compromised prostate cells, and therefore, PSA is released into 
the blood stream. It is reported that the normal PSA range is between 0 and 4 ng/mL. Levels above 
4 ng/mL are indicative of malignancy (The Urology Hospital, 2017). However, it has been stated 
also that raised PSA levels have been found to be associated with benign prostatic hyperplasia 
(BPH), prostatitis and injury to the prostate due to biopsy or catheterisation. Physical activity, 
infection and medication have been found to be associated with either suppression of (latter) or 
increased levels (former) of PSA (Huebner et al., 2015). More importantly, since PCa grows very 
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slow, routine screening is not recommended for the elderly men, i.e., those who are older than 70 
years, and with a life expectancy of less than ten years (USPSTF, 2018). 
 
The advent of PCa screening, has however not been met without some controversies. Many authors 
have reported that over diagnosis increased markedly after the introduction of PSA screening. Two 
categories of over diagnosis have been defined by De Vita and colleagues (2015), namely (1) 
Detection of histologically defined cancers not destined to metastasise or harm the patient, and (2) 
the detection of cancers not destined to metastasise or cause harm in the life span of the specific 
patient. However, PSA is still widely advocated for PCa screening because it is objective, easily 
measured, reproducible, non-invasive and inexpensive (De Vita, et al., 2015). 
 
1.2.3.2  Digital Rectal Examination (DRE)  
This method involves clinical assessment of the prostate gland by the insertion of a gloved finger 
into the rectum ((The Urology Hospital, 2017). The aim of this test is to determine the size and 
consistency of the gland, and also to determine the presence of cancerous nodules. Where nodules 
are suspected, a prostate biopsy is performed (The Urology Hospital, 2017).  
 
It is a recommendation by De Vita and colleagues (2015) that the physical examination should 
focus on a thorough DRE of the prostate, although palpable nodes can sometimes be detected in 
the inguinal or supraclavicular areas. Areas of induration within the prostate, extension through 
the capsule, or involvement of the seminal vesicles should be detected carefully. The authors 
further state that DRE results are associated with pathologic stage and prognosis, and are the 
principal basis for assigning T stage of the cancer (De Vita et al., 2015).  
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The DRE method has been reported by Rubin & Williams (2001) to lack sensitivity and specificity. 
The authors also stated that roughly 50% of suspicious nodules turn out to be cancer, however, 
many cancers are not palpable, and it has been found that many cancers detected by DRE are 
locally advanced and probably not curable. (Rubin & Williams, 2001). The authors further 
mentioned that it is recommended to do a PSA screening before obtaining a DRE, as the 
examination may increase the PSA slightly. However, a DRE performed before obtaining a PSA 
reading has very little impact on PSA values in men without PCa.  The authors  have  also stated 
that where abnormalities are present during DRE or PSA test, further investigations should be 
sought, and these include trans-rectal ultrasound and prostate biopsy (Rubin & Williams, 2001). 
 
1.2.3.3 Biopsy 
Prostate biopsy is performed if the findings with either PSA or DRE, or both are found to be 
abnormal (Leslie & Siref, 2018). A TRUS is used to aid the placement of the biopsy needles that 
are used trans-rectally (Leslie & Siref, 2018). The Ultrasound is used to guide the biopsy procedure 
via a trans-rectal or trans-perineal route. The diagnosis of PCa is confirmed by needle biopsy and 
histological analysis of the biopsy specimens (The Urology Hospital, 2017). 
 
Huebner & Barqawi (2015) have reported that an introduction of 3-D mapping biopsy (3DMB) 
has also displayed a substantial advancement in the evaluation of PCa. The 3DMB has the potential 
to omit a significant number of patients from active surveillance programs and in doing so avoid 
cases of under treatment. It is believed that this improvement in imaging will provide physicians 
with greater confidence and assurance when assessing the most pragmatic course of treatment for 
the patients (Huebner & Barqawi, 2015). 
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The development of 3DMB and focal ablative therapies are helping to elucidate the distinction 
between mortal and non-mortal PCas. The advancement of imaging technology is a crucial factor 
in eliminating the uncertainty that surrounds the treatment selection process and in increasing the 
utilization of active surveillance and less aggressive treatment modalities for the maximization of 
patient quality of life (Huebner & Barqawi 2015). Biopsy has been found to carry a risk of bleeding 
and infection in 3% - 4% of those undergoing the procedure, and is increased with the number of 
cores obtained.  It is also reported that biopsy results are used not only to assign a Gleason score, 
but also to assess the volume and extent of the cancer by (1) determining the number of percentage 
of cores involved by cancer, (2) the amount of cancer in each core, and (3) the total length of 
cancer in all cores. These add important additional staging and prognostic information (De Vita, 
et al., 2015). 
 
Parker et al., (2015) reported that indications for a repeat biopsy after a negative biopsy include a 
rising PSA, suspicious DRE, acinar proliferation, multifocal high grade prostatic intraepithelial 
neoplasia. It is reported that for patients with very aggressive tumours, where PSA levels are 
>20ng/ml and biopsy Gleason score >7, advanced local lesions (T3-4) or symptoms suggestive of 
metastatic disease should have imaging studies including a bone scan (Positron Emission 
Tomography (PET), a Computed Tomography (CT) scan of the chest, abdomen and pelvis (De 
Vita, et al., 2015). 
 
1.2.4 Staging and Grading of PCa 
 
The stage refers to the extent and spread of the disease while the grade refers to the aggressiveness 
of the tumour. The Gleason score, which range from 2 to 10, with 2 representing the well-
differentiated tumours and 10 the least-differentiated tumours, is used to grade the cancer by 
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determining the glandular pattern when compared with a normal prostate (Gul et al., 2011). The 
scores can also be categorised into groups that show similar biological behaviour such as low grade 
(well – differentiated), intermediate grade (moderate) and high grade (poorly-differentiated) (Gul 
et al., 2011). 
 
The authors further state that staging and grading assist in the determination of the extent of the 
disease and also the prognosis, such information is required for the decision making process for 
treatment and management of PCa.  The tumor, node, and metastasis (TNM) staging system is 
used, and it involves the determination of the extent of primary lesions (T-stage), Nodal status (N) 
and distant metastases (M) (Gul et al., 2011). 
 
Parker et al., (2015) have recommended that localised disease should be classified as low risk (T1- 
T2a and GS ≤6 and PSA ≤10), Intermediate risk (T2b and /or GS 7 and / or PSA 10-20), and High 
risk (≥T2c or GS 8-10 or PSA above 20). The purpose of the grading system is to note dominant 
primary pattern and add the next most frequent secondary pattern to give a combined score 
(Underwood et al., 2009). The authors report that where only one pattern of differentiation is seen, 
as often as it applies in small biopsy, the number is then doubled. Aggressive tumours are graded 
(5+5 = 10) and are poorly differentiated, and are characterised by acinar differentiation that is no 
longer apparent in strands of tumour cells or cribriform structures with central necrosis may be 
found. . Moderately differentiated (3+4 or 4+3 = 7) have fused glands or cribriform structures, and 
well differentiated (3, will be doubled) comprise of separated, somewhat irregular, gland or acinar 
profiles that infiltrate into normal glands at the edge of the mass (Rubin & Williams, 2001 & De 
Vita et al., 2015). Parker and colleagues (2015) recommend that Clinical T stage should be 
evaluated by DRE. However, MRI has been found to provide more accurate T staging (Parker, et 
al., 2015). Patients diagnosed incidentally as having PCa following TURP are considered to have 
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a stage T1a or T1b signifying focal and diffuse disease according to Rubin & Williams (2001). If 
a patient has non-palpable disease not detected by imaging, T1c is used. This stage is also referred 
to as Stage I PCa. 
 
Palpable tumour contained within the gland and limited to one lobe is stage T2a and T2b (Stage 
Ⅱ) if both lobes are involved. The authors’ further state that once the tumour has extended through 
the capsule, the stage is T3a (Stage Ⅲ). If involvement is focal or T3b if either seminal vesicle is 
involved. Involvement of the lymph nodes is classified N1-3 (Stage Ⅳ) depending on size (Rubin 
et al., 2001, Parker et al., 2015). 
 
Prostate cancer spread has been described by Underwood and colleagues (2009) to occur in three 
modalities namely (1) direct, (2) via lymphaticts, and (3) via blood. Direct spread involves stromal 
invasion, prostatic capsule, urethra, bladder base and seminal vesicle. Spread via lymphatics 
includes spread to the sacral, iliac and para-aortic nodes. When cancer spreads via the blood, it 
metastasises to the bone (pelvis, lumbosacral spine and femur) lungs and liver (Underwood et al., 
2009). 
 
This spread of PCa is monitored using a number of imaging techniques, of note is the Galium-68-
PSMA PET/CT Scan for cancer imaging. Accurate staging of patients with PCa is important for 
therapeutic decision-making (Hofman et al., 2018). The authors further state that the use of 
diagnostic imaging is showing rapid growth worldwide, and Ga-68_PSMA ligand PET/CT 
promises accurate staging of primary prostate cancer and re-staging after biochemical recurrence 
(Hofman et al., 2018).   
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1.2.5 Management of Prostate Cancer 
 
Prostate cancer diagnostic and treatment guidelines of South Africa, outlines the different 
treatment modalities of PCa, according to the staging and grading of the PCa. The different stages 
and their treatment modalities are discussed below: 
 
1.2.5.1  Clinically Localised Prostate Cancer 
It is reported that some tumours of the prostate grow slowly and remain asymptomatic, so the man 
will eventually die with the tumour, but not from it (Rahman et al., 2017). Also, depending on the 
characteristics of the cancer, age and comorbidities, some men would benefit greatly by aggressive 
treatment, whereas others would suffer harm (Parker et al., 2015). Numerous studies have reported 
that at diagnosis approximately 70% of men will have the cancer confined to the prostate gland 
(Underwood et al., 2009).  
 
With the advent of PSA screening and imaging of the PCa, progression of the cancer can be 
identified at its early stages in order to increase survival and quality of life (Lipke & Sundaram 
2005). A variety of treatment modalities for PCa have been identified and evaluated by numerous 
studies as observed in this study during literature review.  
 
Treatment modalities for clinically localised PCa as listed in the South African Prostate cancer 
diagnostic and treatment guidelines include (1) deferred treatment which includes (active 
surveillance and watchful waiting), (2) Surgical Interventions (which include Radical 
Prostatectomy), (3) Radiotherapy, (3) Cryotherapy, and (4) Androgen Deprivation Therapy 
(Segone et al., 2013). 
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1.2.5.1.1 Active Surveillance (AS) 
De Vita and colleagues (2015) define “active surveillance” as a planned treatment of monitoring 
a patient with a potentially curable PCa (PSA < 10ng/ml, GS ≤ 6, T1 – 2a, PSA density <0.15 – 
0.2 and ≤ 50% of PCa in any biopsy core). This is based on the likelihood that the cancer will 
progress, delaying active treatment until signs of progression to a more aggressive, potentially 
lethal cancer are detected (De Vita, et al., 2015). It is recommended that patients should commit 
to a regular follow up with DRE and PSA. A repeat biopsy is indicated after 12 – 24 months or if 
there is any sign of disease progression by examination or markers (Segone et al., 2013). 
 
1.2.5.1.2 Wait-and-See Approach 
It is reported that in elderly non-symptomatic patients, discovered during a screening test, watchful 
waiting combined with active surveillance is recommended. This process involves close 
monitoring of the patient’s condition without any application of therapy. Where changes occur in 
symptoms and / or lab tests results, treatment may be considered and implemented. However, such 
treatment, although of a limited therapeutic value, is important for timely discovering and relieving 
the painful symptoms, thus substantially improving the patient’s quality of life (Morgia et al., 
2013). 
 
1.2.5.1.3 Surgical Interventions 
Morgia et al. (2013) listed two types of radical prostatectomy, namely open radical prostatectomy 
and laparoscopic radical prostatectomy. The open radical prostatectomy is the option for the 
treatment of early detected prostate cancer, provided the patient is in good health and the tumour 
is localised. It includes the removal of seminal vesicles and the surrounding tissue (Morgia et al., 
2013). Two main techniques of radical prostatectomy have been identified, namely retro pubic and 
perineal prostatectomy.  
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In retro pubic-prostatectomy, the prostate is removed via an incision made in the abdominal wall, 
with concomitant elimination of nearby lymph nodes. The process can be either anterograde or 
retrograde. In perineal prostatectomy, the prostate is cut out through an incision made in the 
perineum area. A separate abdominal incision shall be performed for the removal of the lymph 
nodes (Morgia et al., 2013). 
 
The laparoscopic radical prostatectomy was introduced in the 1990s (Lipke & Sundaram, 2005). 
It is characterised by less aggressive surgical procedures. The removal of the prostate is via small 
incisions performed by laparoscopic surgical tools. It is reported that this technique appears to 
produce results at least as good as the open radical prostatectomy. Lipke & Sundaram, (2005) 
further stated that laparoscopic radical prostatectomy (LRP) has been found to be beneficial to the 
patient by causing less blood loss and less pain, as well as shortening the patient’s hospital stay 
and recovery time. Side effects rates after LRP have been found to be similar to those following 
open prostatectomy. Bladder control recovery may take longer, however, the nerve sparing 
procedure for erectile function restoration is similar to the open surgery (Margio et al., 2013). 
 
1.2.5.1.4 Radiation Therapy 
Sack et al (2016) stated that cryotherapy/cryosurgery and radiotherapy are common primary, 
salvage and/or adjuvant treatment options offered for the management of localised prostate cancer. 
Two types of radiation therapy for the treatment of PCa have been identified namely, external 
beam radiation therapy (EBRT) and internal radiation therapy or brachytherapy. In EBRT a dose 
of ionising radiation is generated by an external x-ray source and are delivered to the target area, 
the prostate (Vanneste et al., 2016).  
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Brachytherapy uses radioisotopes such as Iodine-125, Strontium- 89 and Palladium – 103. The 
radioisotope of choice is implanted enclosed in a protective radioactive substance sealed in a 
special needle, seed or catheter wire, allowing the ionizing radiation to escape and destroy the 
tumour and the surrounding tissue and preventing it from moving further and dissolving in body 
fluids (Margio et al., 2013). This process prevents damage to healthy tissues, as only the tumour 
and the specific surrounding area affected. The ideal candidates for brachytherapy are patients with 
PSA <10 ng/ml, Gleason <6, CT1 – 2, IPSS <10, Qmax>15 ml/sec and prostatic volume <50cc 
(Margio et al., 2013). 
 
Brachytherapy has been found to be a valid therapeutic option, yielding excellent results that are 
comparable with those of radical surgery and are considered to be better than those of EBRT. The 
disease – free survival rates have been observed to reach 70% - 75% following 12 years post – 
therapy (Margio et al., 2013). EBRT and brachytherapy have been found to be potentially curative 
therapies for PCa (Vanneste et al., 2016).  
 
1.2.5.1.5 Cryosurgery  
Cryosurgery is also known as cryoablation or cryotherapy. It is a method whose main mechanism 
of injury is by coagulation necrosis (Rodriguez et al., 2013). The effect of ice on cell membranes 
is an immediate disruption by mechanical direct effect. The ultimate goal of cryotherapy is cell 
death by necrosis and apoptosis (Rodriguez et al., 2013).  
 
Spinal or epidural anaesthesia is applied during this procedure, and TRUS is used to guide the 
process. Ultrasound images are vital to ensure that tumour destruction occurs without too much 
damage to nearby tissues. Warm salt water is circulated concomitantly through a catheter in the 
urethra, to prevent it from freezing. However, it was reported that this procedure is only 
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advantageous for early detected cancers, and less effective for more advanced prostate tumours 
(Sack et al., 2016). 
 
1.2.5.1.6 Androgen Deprivation Therapy (ADT) 
Androgen Deprivation therapy, is defined by Gravis as the standard treatment for metastatic 
disease, and it includes surgical and/ or medical castration and has been used for decades (Gravis, 
2018),   Medical castration is achieved through the use of gonadotropin – releasing hormone 
receptor agonists or antagonists (El-Amm & Aragon-Ching, 2019). AR antagonists competitively 
bind to the AR and block the binding of endogenous androgens and thus interrupt the androgen-
dependent cellular cascade that leads to progression of prostate cancer (Xu & Qiu, 2019). 
 
It is reported that testosterone and the more potent dihydrotestosterone are the two main androgens 
that are responsible for the growth of the prostate by binding to the androgen receptor (El-Amm 
& Aragon-Ching, 2019). The ADT, according to Jang and colleagues (2016) includes Luteinising 
hormone releasing hormone analogues such as Goserelin that act by reducing the amount of 
testosterone produced by the testes. It is reported that in order to avoid the initial flare effect when 
these are administered, anti – androgen therapy with flutamide or bicalutamide should precede or 
co-administered with LHRH agonist for at least 7 days (Jang, et al., 2016).  
 
Goserelin is an agonist analogue of gonadotropin-releasing hormone that induces hypogonadism 
by reducing the secretion of gonadotropin and therefore testosterone (Bolla et al., (1997).  
Goserelin is given as a subcutaneous dose of 3.6mg monthly or 10.8mg every 3 months; however, 
in other studies it has been administered subcutaneously every 4 weeks starting on the day of 
irradiation (Bolla et al., 1997). 
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The following advantages have been associated with the use of Goserelin: (1). Studies have shown 
that it improves overall survival of patients with locally advanced prostate cancer. (2). Goserelin 
has been found to show advantages over radiotherapy in terms of local control, incidence of distant 
metastasis and progression –free survival. (3). The use of the depot preparation of a Luteinising 
hormone releasing hormone (LHRH) analogue to supress gonadotropin and sex hormone secretion 
offers the convenience of once a monthly injections when LHRH analogues are required for long 
term treatment of elderly patients with prostatic cancer and children with precocious puberty 
(Sciarra et al., 2016). 
 
De Vita et al., (2015) reported that even though ADT has been widely used for decades, there are 
numerous side effects that are associated with the use of ADT and these have been grouped under 
the “androgen deprivation syndrome”, and include hot flushes, a decrease in libido, erectile 
dysfunction, impotence, fatigue, anaemia, weight gain and alteration in fat metabolism, loss of 
muscle mass and weakness, bone loss, a decrease in mental acuity, mood swings, personality 
changes, memory loss, depression, insomnia and cardiovascular events (De Vita et al., 2015).  
 
Combination therapy has been found to enhance efficacy through more complete inhibition of 
major pro-survival pathways or suppression of multiple pro-survival factors, and has been proven 
very effective for the treatment of advanced cancers (Dong, et al., 2018). Combination therapies 
of ADT and chemotherapeutic agents have been investigated for the treatment of various stages of 
PCa in a number of clinical trials that included the CHAARTED, SWOG – 9916 and STAMPEDE 
to name a few. Progression from low risk and intermediate risk to high risk PCa requires treatment 
modalities that are properly planned based on the presentation of the disease and other patient 
factors and assessment of potential outcomes.  
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1.2.5.1.7 Chemotherapy for Advanced Prostate Cancer 
Chemotherapy involves the use of cytotoxic drugs to kill the cancer cells while simultaneously 
limiting undesirable and unacceptable toxicity to the neighbouring cells (Buchler & Harland 2007). 
Generally, different combinations or drugs (or drug regimens) are administered intermittently over 
two to three weeks to allow for the recovery of the bone marrow and restoration of the immune 
function in between treatment courses (Mkele, 2010).   
 
Factors to be considered when choosing the most appropriate drugs to use for a chemotherapy 
regimen include the type of cancer being treated, the stage of the cancer, the tumour size, the site(s) 
of the metastases, the patient’s age and general state of health, the presence of other serious co-
morbidities, as well as the cost of the drug treatment (Mkele, 2010). 
 
Mitoxantrone and estramustine (Emcyt®), were the first approved chemotherapy agents that were 
utilised for PCa patients to help control pain to relieve symptoms associated with their metastatic 
disease (Shalini et al., 2013). Mitoxantrone belongs to the anthracyclines group of anti-tumour 
antibiotics that interfere with the enzymes involved in DNA replication. These agents function in 
all phases of the cell cycle. High doses of these drugs have been associated with cardiac damage, 
as a result life time dose limits are often placed on these drugs (Mkele, 2010). Prednisolone is often 
used along with mitoxantrone to improve survival, quality of life and pain response (Collins et al., 
2006). 
 
Other than mitoxantrane, docetaxel which belongs to the large plant-derived taxane group of 
chemotherapy drugs is also used a first-line drug to in patients with PCa (Segone et al., 2013). It 
causes cell death by inhibiting depolymerisation of the contractile protein tubulin during mitosis 
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(Tannock et al., (2004); Chiuri et al., 2009). Taxanes are used to treat many other types of cancers 
including breast, lung, myelomas, lymphomas and leukaemia (Mkele, 2010). 
 
However, androgen suppressor regimens have been widely used as either first line prior to 
chemotherapy use or as an adjunct to radiotherapy in order to suppress the secretion of testosterone 
in patients with advanced stage (Oefelein, 2008).  In South Africa,  Goserelin (Zoladex®) continues 
to be used as one of the primary regimen for androgen suppression in the public sector. 
 
 Fizazi and colleagues (2015) reported that in 2004, following results from the TAX 327 study, 
Docetaxel was approved as first – line chemotherapy for the treatment of patients with mCRPC 
and was the first drug to demonstrate improved survival in this setting.  
 
With the advent of systemic agents that have been approved for the treatment of mCRPC, the goals 
of treatment have been optimised to include pain management where bone metastasis have been 
observed. In the STAMPEDE and CHAARTED trials, Zoledronic acid (a bisphosphonate), 
Radium 23 (Radioisotopes) and Denosumab (a rank ligand inhibitor) have been used as 
monotherapy or in combination with chemotherapy for palliation in advanced PCa, especially in 
men with high-volume, osseous metastatic disease (Teo et al., 2019; Parker, et al., 2015). 
 
Numerous authors have reported that patterns of disease development differ from patient to patient. 
De Vita, et al.,(2015) stated that the pattern that develops in a patient is influenced in part by the 
extent of disease at the time ADT was first initiated, therefore, the therapeutic objective for 
mCRPC patients is to prevent development of bone metastasis, and the likelihood varies highly 
between patients. 
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Overall survival, quality of life, delayed disease progression have been defined in numerous 
studies as the goals of treatment. The choice of treatment is dependent on an informed patient 
decision and also on the availability of treatment, costs and complications (Segone, et al., 2013). 
In the 20th century the FDA approved six systemic agents following evidence of improved overall 
survival in patients with different PCa states. The literature review has demonstrated that many 
research studies are being undertaken worldwide to further elucidate PCa treatment options. With 
the advent of chemotherapy, chemotherapy in combination with ADT, palliation with 
bisphosphonates, and immunotherapeutic agents, the use of radioisotopes has also been 
investigated.  
 
1.2.5.1.8 Radiopharmaceuticals/Targeted Nuclear Medicine 
Chemotherapy is often less effective in carcinomas, such as the non-Hodgkins lymphomas, 
because some cancer cells are inaccessible to drugs. Therefore radioactive isotopes emitting β 
and/or ϒ rays, such as iodine-131 (I-131) and lutetium-177 (Lu-177) have been used effectively 
to kill cancer cells that cannot be reached by commonly used cytotoxic drugs (DeNardo et al., 
2004).   
 
Radiopharmaceuticals are medicinal formulations containing radioisotopes which are safe for 
administration in humans for diagnosis or therapy (WHO, 2008). Targeted radionuclide therapy, 
therefore, involves the use of radiopharmaceuticals to selectively deliver cytotoxic levels of 
radiation to a disease site, as this would potentially deliver the absorbed radiation dose more 
selectively to cancerous tissues (Jadvar, 2017) 
 
Radioactive iodine-131 (I-131) plays a significant role as an adjunct radionuclide therapy for the 
treatment of thyroid cancer in particular (Luster et al., 2017). Iodine-131 behaves like a “magic 
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bullet” that accumulate in the thyroid follicular cells through the sodium iodide symporter (NIS), 
also known as cotransporter, protein and kills cells it penetrates by β decay mode (Ambikalmajan 
and Furn, 2015).  
 
The I-131 emits β and ϒ particles thereby killing thyroid cells and decreasing thyroid hormone 
production (Al-Qahtani et al., 2014). I-131 has been found to have potential antineoplastic activity 
and its therapy is associated with substantial albeit rare side effects, while gastro-intestinal 
problems, salivary and lacrimal gland complications, gonadal dysfunction have been reported 
(Schlumberger et al., 2012).  
 
Chemically, lutetium belongs to one of the two special groups of the Periodic Table called the 
lanthanides, which starts with lantham (La, Z= 57), and ends with lutetium (Lu, Z= 71). Lutetium 
is a medium-energy β-emitter with a maximum energy of 0.5 MeV and a maximum tissue 
penetration of 2mm (European Medicines Agency 2016). The average β energy is equivalent to 
0.13MeV. Lutetium also emits low energy gamma (ϒ) rays at 208KeV (11%) and 113 KeV (6.4%), 
allowing scintigraphy and subsequent dosimetry with the same therapeutic compound if needed 
(European Medicines Agency, 2016). 
 
In South Africa (SA) Lu-177 is used only under strict Section 21 of the Medicines and Related 
Substances Act (Act 101 of 1965) for the treatment of many different cancers both in public and 
private settings. However, Brazil and Germany have been listed as the countries in which Lu-177 
is registered under the respective drug regulatory agencies (Rahbar et al., 2017). Recently, the 
FDA in the US approved Lu-177 dotatate injection, for intravenous use (Choy, 2018).   
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It is reported by the EMA, that the shorter β range of Lu-177 compared to other radio therapeutic 
agents such as Yttrium provides better irradiation of small tumours, sparing surrounding tissue and 
low energy, low abundance gamma (ϒ ) emissions which are useful for imaging (Kabasakal et al., 
2017).  177Lu- decays to Hafnium (Hf-177), with a half-life (t1/2) of 6.647 days. This relatively 
long t1/2 provides logistic advantages that facilitate its supply to other locations far from 
manufacturing sites (European Medicines Agency., 2016). When labelled with therapeutic 
radionuclides e.g. 177Lu - n.c.a-PSMA, peptide molecules (PSMA in this case), have a potential to 
destroy receptor-expressing tumours, an approach referred to as peptide receptor radionuclide 
therapy (PRRT) (Ambikalmajan and Furn, 2015). 
 
177Lu – PSMA radioligand therapy (LuPRLT) is mainly used for patients with mCRPC who are 
resistant to established drugs (von Eyben, et al., 2019). It is for this reason therefore, that this study 
aims to compare the costs of treatment of patients with mCRPC treated with standard 
chemotherapy compared to 177Lu – n.c.a PSMA at Steve Biko Academic Hospital. 
 
1.3 Economic Burden of Cancer 
 
The costs of treating cancer escalates to billions of dollars per annum, globally. Medical 
expenditures for PCa in America, were estimated to be $11.85 billion in 2010 and projected to 
reach $16.34 billion in 2020 (Chilira et al., 2011). The economic impact of cancer is now a reality 
and is expected to continue to rise causing concern across all countries, wealthy or poor 
(Vanderpuye & Yarney, 2014). In Africa, most patients and their families have to bear the cost of 
treatment from already meagre resources. Budget allocations imbalances, which favour 
communicable diseases, contribute to the low percentage of cancer treatment resources 
(Vanderpuye & Yarney, 2014). 
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In South Africa, the Medicine and Related Substances Act, Act 101 of 1965, was used to introduce 
the Single Exit Price (SEP), for medicines in SA, in August 2004. The SEP is the price at which a 
manufacturer must sell to all pharmacies, irrespective of volume sold. The regulations require that 
the extent of the price adjustment should be based on inflation indicators and the need to ensure 
the availability, affordability and quality of medicines and scheduled substances in the Republic 
(Mngadi, 2014).  
 
However, due to the patent laws, Kahn (2017) stated that these allow the manufacturing companies 
to price cancer drugs at unaffordable prices to the general public and also those also covered by 
Medical Aids in South Africa. Various cases have been cited, where new cancer treatments are not 
affordable due to high costs, and the SEP regulations do not apply. Therefore, economic 
evaluations of various cancer treatments using, either single or combinations of strategies such as 
cost-utility, cost-effectiveness, cost-minimisation and/or cost-benefit analyses, are needed. 
 
Globally, the ever increasing costs continue to hamper access and availability of effective cancer 
drugs to multitudes of desperate patients who urgently need therapy for survival (The Lancet, 
2018). It is reported that in South Africa, there is limited competition between suppliers of 
medicinal products, especially cancer drugs due to patent laws (Gray, 2009). Therefore, recently, 
calls have been made to change intellectual property regime and patent laws for medicines, because 
the current system inhibits competition and keeps drug prices at unaffordable levels (Kahn, 2017).  
The management of PCa remains complex depending on the stage at which it is detected, age of 
the patient, presence of co-morbidities and treatment norms and strategies employed in a particular 
health system (Saraf, 2013). 
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With the advent of new PCa therapies, it is important to understand the economic impact of their 
adoption in health plans (Bui et al., 2016).  However, for the treatment of metastatic, castrate-
resistant prostate cancer, the FDA has not approved any PSMA targeting radionuclide therapy 
(Nitipir et al., 2017).  
 
Screening and imaging of PCa forms part of the costs that are incurred for the treatment of PCa. 
Bone scintigraphy and PET/CT scan costs need to be taken into consideration towards PCa costs. 
Irrespective of the treatment employed, the clinical and economic implications have been observed 
to be large (Saraf, 2013). 
 
1.4 Pharmacoeconomics Tools 
 
Baldi and Kumar define Pharmacoeconomics as “that branch of Healthcare Economics that 
identifies, measures, and compares the costs and consequences of drug therapy to healthcare 
systems and society” (Baldi & Kumar, 2013). Economic evaluation methods or tools such as cost- 
utility analysis (CUA), cost-effectiveness analysis (CEA), cost- minimisation analysis (CMA) and 
cost-benefit analysis (CBA) are increasingly being used by decision makers to inform resource 
allocation and development of healthcare policies (Jacobsen et al., 2020, & Baldi et al., 2013).  
 
1.4.1 Cost-utility Analysis 
CUA is reported to be the best economic evaluation method to make decisions about health 
resource allocation. The CUA compares the costs of different procedures with their outcomes 
measured in “utility based” units, that sis units that relate to a person’s level of wellbeing 
(Robinson, 1993).  
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In CUA, health gain is measured by an artificial unit quality-adjusted life-years (QALYs), which 
combines the quality of life (QoL) and the survival benefit of patients (Bodrogi & Kalo, 2010). To 
calculate the QALYs, the expected life-years are weighted by their quality. The quality weight of 
perfect health 1 (one), utility weight of death 0 (zero). Comparison between alternative procedures 
or programs can then be based on the marginal cost per QALY gained (Bodrogi & Kalo, 2010; 
Robinson, 1993). 
 
1.4.2 Cost-effectiveness Analysis  
 
Cost-effectiveness analysis is concerned with technical efficiency issues such as the identification 
of ways to achieve goals or spending a given budget (Miller 2009). Health benefits are measured 
by natural units and traditional clinical trials end points (Bodrogi & Kalo, 2010). Clinical 
diagnostic or device outcomes such as mmHg blood pressure reduction or mmol/L LDL 
cholesterol reduction can be used in CEA, only if improvement in these intermediate outcomes 
results in similar improvement in hard end points. Measurements costs are done in monetary terms 
(Bodrogi & Kalo, 2010). 
 
It is reported that CEA are relatively straightforward to carry out and are sufficient for addressing 
many health questions in health care. However, the general drawback is that health programmes 
with different aims cannot be compared with one another using CEA (Miller, 2009). Miller (2009) 
also concludes that CEA not only assumes that the outcome of the health programme is worthwhile 
but also that it is the most appropriate measure. 
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1.4.3 Cost-Minimisation Analysis  
 
Walter & Zehetmayer (2016) state that “CMA is a pharmacoeconomic tool that is used and applied 
when comparing multiple drugs of equal efficacy and equal tolerability”. Once the health 
consequences are established to be the same, a CMA would compare all cost between treatments 
to determine the option with the least cost (Baldi & Kumar, 2013).  The objective of CMA is to 
select the least costly intervention among multiple equivalent. However, CMA cannot be used to 
evaluate programmes or therapies that lead to different outcomes. It is appropriate to use CMA 
when comparing two or more therapeutically equivalent agents or alternate dosing regimens of the 
same agent (Bodrogi & Kalo, 2010). Measurement or assessment of costs in CMA is measured in 
monetary terms (Walter & Zehetmayer, 2016). 
 
1.4.4 Cost-benefit Analysis (CBA) 
 
Baldi & Kumar, (2013) describe CBA as the most comprehensive and the most difficult of all 
economic evaluation techniques. CBA is reported to involve the assignment of monetary value to 
the benefits, thereby facilitating easy comparison of costs and benefits, as a result totally different 
interventions can be compared, making it a useful tool (like CUA) for resource allocation by 
policy-makers (Bodrogi & Kalo, 2010).  CBA is a basic tool that allows for the identification, 
measurement, and comparison of the benefits and costs of a programme or treatment alternative 
(Baldi & Kumar, 2013).  
 
The benefits of CBA are that it is employed when comparing treatment alternatives in which the 
costs and benefits do not occur simultaneously. Also, CBA can be used when comparing 
programmes with different objectives because all benefits are converted into dollars and to 
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evaluate a single programme or compare multiple programmes (Walter & Zehetmayer 2016). The 
benefits realised from a programme or treatment alternative are compared with the costs of 
providing it. Both the costs and the benefits are measured and converted into equivalent dollars in 
the year in which they will occur. Future costs and benefits are discounted or reduced to their 
current value (Bodrogi & Kalo, 2010). This method addresses the question of willingness to pay 
for the intervention being rendered. However, it may ignore intangible benefits (pain, anxiety, and 
stress) that are difficult to express in monetary terms (Baldi & Kumar, 2013). 
 
1.5 The Aim of this Study 
 
The aim of the study was to analyse the costs associated with treating mCRPC with standard 
chemotherapy regimens when compared with the costs incurred for mCRPC in SA. These data 
were vital to inform policy, funds allocation for PCa treatment both in public and private health 
care. 
 
1.6 Study Objectives 
 
a) To investigate the direct medical costs incurred by PCa patients treated for mCRPC with 
standard chemotherapy at selected public hospitals in South Africa. 
b) To investigate the direct medical costs incurred by PCa patients treated for mCRPC with 
targeted nuclear medicine (177Lu –n.c.a-PSMA) standard chemotherapy at selected public 
hospitals in South Africa.  
c) To compare the costs and or benefits of treating mCRPC patients with general 
chemotherapy versus targeted nuclear medicine (177Lu –n.c.a-PSMA) using either the 
private or public economic model as per hospital’s model. 
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1.7 Research Questions 
 
a) What are the direct medical costs of treating mCRPC with standard chemotherapy regimen 
such as docetaxel /prednisone/goreseline in South Africa? 
b) What are the direct medical costs of treating mCRPC with targeted nuclear medicine such 
as 177Lu-n.c.a- PSMA in South Africa?  
c) What are monetary benefits of treating PCa with docetaxel//prednisone/ goreseline regimen 
versus Lu-177-n.c.a- PSMA? 
d) What is the overall survival for patients treated with standard chemotherapy compared to 
the patients treated with targeted nuclear medicine? 
e) Were there any significant biochemical responses observed during treatment? 
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CHAPTER 2:  Methodology 
 
2.1 Approval of Research Protocol 
 
The study protocol, and subsequent annual re-certifications, was approved by the UKZN 
Biomedical Research Ethics Committee (Ref.: BE458/18); the University of Pretoria Faculty of 
Health Sciences Research Ethics Committee (Ref.: 747/2018)061/09); KwaZulu-Natal 
Department of Health (as well all applicable authorities/head of departments at the Inkosi Albert 
Luthuli Central Hospital & the Addington Hospital, Durban); the Gauteng Department of Health 
(as well all applicable authorities/head of departments at the Steve Biko Academic Hospital). 
Approval was obtained from the NTP Radioisotope, which also signed a memorandum of 
understanding with the UKZN, please refer to Addendum A.  
 
2.2 Study Design and Setting 
 
This was a retrospective and prospective inferential study, conducted mainly on patients aged >18 
years at Steve Biko Academic Hospital (SBAH), Pretoria, the Inkosi Albert Luthuli Central 
Hospital (IALCH) in Durban, South Africa and Addington Hospital, Durban. The patients who 
were referred to the treatment centres between the periods 1 January 2017 and 24 November 2019 
were included in this study.  
 
In particular, data were collected from the Nuclear Medicine Department (at the SBAH) and from 
the Medical Oncology, Urology, Radiation Oncology as well as Nuclear Medicine Divisions at the 
IALCH. Patients were identified using MediTech™, a paperless, electronic hospital information 
system at the IALCH. MediTech™, a computerised data system, in which data is stored on tables 
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in the data repository, a Standardized Query Language (SQL) for requesting information from a 
database. Clinical and billing (charges) from the data repository using SQL extraction queries with 
parameters (e.g. required ICD codes, patient race, age, medicine charges, imaging and laboratory 
costs). Identified patients were then grouped by ICD-10 Codes listed on the data base for PCa, 
were sourced. This system uses the same race categories as those used by the South African census 
to categorise race in South Africa - namely Asian, Black, Coloured, White and other. At SBAH, 
the patient records (files) were manually accessed, and a thorough manual audit was performed to 
identify patients who were treated for mCRPC at this hospital between the period of 1st January 
2017 to 24 November 2019. Data extracted from the patient files was recorded in the data 
collection sheet. 
 
2.3  Study Population & Inclusion Criteria 
The study population was prostate cancer patients with mCRPC that were treated at the chosen 
research sites from the 1st of January 2017 to the 31st December 2019 within the Nuclear Medicine 
Unit at Steve Biko Academic Hospital and Oncology, Urology, Radiation Oncology and Nuclear 
Medicine units at IALCH Hospitals respectively. All prostate cancers as defined in the 
International Classification of Diseases (ICD) were categories into four prostate cancer groups 
namely Carcinoma in situ (D07.5), Benign neoplasm of the prostate (D29.1), Prostate neoplasm 
of unknown behaviour (D40.0) and Malignant neoplasm of the prostate (C61). All patients with 
the ICD-10 Code C61 were included in the study and patients with the ICD -10 Code patients 
(D07.5, D29 and D40.0) were excluded.  
 
Critical data points such as race, patient age at diagnosis, patient age at last visit, PSA value (in 
mg/ml), chemotherapy, laboratory, imaging, in-hospital and out-patient costs were analysed and 
included as direct medical costs. Pain management, side effects management and adjuvant therapy 
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costs were also analysed. Indirect medical costs such as transportation and personal care were not 
included in the study. 
 
Patients were excluded if the records showed that treatment ceased prior to the treatment period, 
were not of male gender, were under the age of 18, were male diagnosed with mCRPC but treated 
with other Nuclear Medicine Radioisotopes other than Lu-PSMA, and were coded with ICD 10 
Code C61, but no chemotherapy treatment was available on the records. Patient records of those 
who demised during the study period were included. Records with the following information were 
included in the costs comparison analysis of standard chemotherapy regimen versus targeted 
nuclear medicines for PCa at these hospitals. 
 
2.3.1 Demographic Information 
 
Patient age, race, gender and medical record number were used for the identification of the patient 
and were necessary for extraction of data from the MediTech™ system as well as manual analysis 
of the patient files. 
 
2.3.2 Dates of First and Last Visits 
 
The dates of first and the last visits were used for determining the status of the patient during the 
study. That is whether the patient was still alive, deceased or lost to follow up. The date of the first 
visit was also used to link the patient’s current age with the age at diagnosis. This was crucial in 
order to determine the overall survival of the patient since diagnosed with PCa. 
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2.3.3 Clinical Assessment Records 
 
The Gleason score, where applicable, and PSA levels or frequency of testing were recorded. This 
information was necessary for the staging of the PCa as well as the monitoring of biochemical 
recurrence. 
 
2.3.4 Out-patient and In-patient Days for 2017-2019 
 
This information was used to determine the number of visits in the out-patient (day visit to consult 
with the oncologist, radiologist, urological specialist or first time consultation and patient is not 
admitted to a ward), emergency as well as in-patients (hospital admission) in order to calculate the 
costs incurred for hospitalisation and consultation in the Nuclear Medicine, emergency unit, 
urology and medical and radiation oncology wards during the study period. 
 
2.3.5 Imaging and Screening Details 
 
Information related to the imaging and screening tests performed for the included patients was 
necessary to calculate the costs related to each of the therapeutic options. 
 
2.3.6 Treatment Regimens 
Chemotherapy and nuclear medicine regimens details were required in order to calculate costs 
associated with each treatment. This information was also used to determine the inclusion or the 
exclusion of the patients during the study period. 
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2.3.7 Hospital Classification Coding System 
 
Hospital classification coding system was recorded for each patient in order to assign costs. This 
was done in order to elucidate the mode of payment (state, medical aid or out of pocket). According 
to June (2002) the national department of health (NDoH) has classified patients into two main 
groups for the purposes of service determination, namely full paying patients and subsidised 
patients. Full paying patients include externally funded patients, patients being treated by their 
private practitioner and other categories of non-South African citizens and are liable for full 
uniform patient fee schedule (UPFS) fees. Subsidised patients are patients who do not fall in the 
category of full paying patients, and are further categorised based on their ability to pay for health 
services into four categories: H0, H1, H2 and H3. The fees payable by subsidised patients are 
expressed as a percentage of the fees payable by full paying patients as determined by the (UPFS). 
H0 patients qualify for full subsidisation, H1, H2, and H3 patients qualify for partial subsidisation 
(June, 2002).  
 
2.3.8 Patient Status 
 
The patient status during the study was classified into three categories alive, deceased and lost to 
follow up (where patients could not be accounted for between 2017-2019). This information was 
necessary in order to determine both mortality and overall survival during the study period. 
 
2.4 Sampling Procedure 
 
At the IALCH, the MediTech™ system was used as the primary tool to extract data for patients 
diagnosed with PCa. The patient information on MediTech™ was stratified by ward and ICD 10 
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codes. The ICD-10 code C61 (metastatic neoplasm of the prostate) is used to determine the sample 
of adult male patients aged 18 years and above to be observed under study. The patients are also 
sampled based on the chemotherapy regimen that they received from this treatment centre for the 
period between 1 January 2017 to 24 November 2019. Both live and deceased patient records for 
the period under study are included as the sample for this study. The exclusion criteria includes 
patients whose records indicate other ICD-10 codes of PCa, that is not malignant, as well as no 
treatment with chemotherapy.  At the SBAH the patient files were used as the primary data source. 
Sample included male patients aged 18 years and above, diagnosed with mCRPC and treated with 
nuclear medicine 177Lu-n.c.a- PSMA between 1 January 2017 – 24 November 2019. 
  
2.5 Costing Model and the Costs Analysed 
 
For each patient in our sample we calculated expenditure as the total of all costs in the files or 
MediTech™ records over the 2017-2019 period, based on the treatment cycles received for 
chemotherapy regimen, nuclear regimen, imaging, laboratory screening, as well as hospitalisation 
costs where applicable. We collected imaging (Gallium-68) PET/ CT Scan, renal imaging, tumour 
localisation imaging costs and laboratory screening costs (FBC, LFTs U&E) from the Nuclear 
Medicine unit and the National Health Laboratory services respectively. Lu-PSMA costs were 
collected from the planning charts in the patients files. Any other costs that were related to the 
treatment regimens, such as technical costs, renal imaging costs, as well as the prophylaxis and 
aminosteryl costs were collected from the patients files. 
 
At the IALCH, the MediTech™ system to extract most of the data through the ABC (activity-based 
costing) model, was used. This includes both the ABC Facility rates, where the 2018/2019 costing 
rates were used as they were the latest completed financial year and the latest average costs. The 
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ABC Facility costs are the average costs of the patients visit (out-patient department (OPD) or 
Emergency Unit) or in-patient stay. The ABC Facility costs were based on the visit charges. The 
visit charges contain all visit details where the patients listed on the Meditech™ system have been 
ICD 10 coded between 1 January 2017 and 24 November 2019. The visits charges in the ABC 
Facility Cost model include both the out-patient and in-patient costs as well as the treatment costs 
incurred during the study period for the chemotherapy regimen. 
 
All the chemotherapy costs on MediTech™ using the visits information from the ABC costs, were 
extracted and downloaded for analyses. Where chemotherapy costs were not available, we 
searched on MediTech™ for chemotherapy regimen issued to the patients during the OPD or in-
patient or emergency unit. The frequency of doses supplied was also recorded in order to aid in 
the calculation of the total costs incurred. On MediTech™, the chemotherapy costs were 
standardised for each treatment regimen regardless of combination used, therefore we adopted the 
same costing for the data where costs were not available, but the regimen was known. We also 
noted the treatment cycles for each regimen in order to calculate the final costs. From the data 
obtained we grouped patient chemotherapy regimen into eleven different regimens as per 
monotherapy or combination used per patient during the study period. 
 
In-patient days costs for the period of 2017-2019 were extracted from MediTech™ for the total 
number of in-patient occupancy days as ICD 10 coded for Prostate Cancer (ICD-10 code C61). 
These costs were linked to the patient’s medical record number. Laboratory and imaging costs 
were extracted from MediTech™ system and were stratified per ward where the patient visited or 
was admitted during the study period. The costs of bone palliation treatment for patients with 
mCRPC were analysed and costs of the treatment were calculated.  
 
49 
 
Although PCa cancer treatment is associated with a variety of side effects, only the cost of 
treatment for prevention of nausea and vomiting was considered, as this was the only available 
data. The costs of prednisone as the regimen used in combination with docetaxel in chemotherapy 
as part of the prophylaxis or comprehensive patient care, was analysed.  
 
Expenditure on radiotherapy as a monotherapy was excluded. However, for patients who were 
concurrently treated with radiotherapy, such costs were included as part of the OPD costs. 
  
2.6 Data Analyses 
 
Data were analysed using the Statistical Program IBM SPSS, Version 26 for statistical 
manipulations and analyses. The data analysis did not include health outcomes such as life-years 
gained and quality adjusted life-years (QALYs). Descriptive statistics for frequencies, means, 
minimum and maximum values, and where applicable standard deviation were used.  
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CHAPTER 3: Findings 
 
3.1 Chemotherapy Cohort  
 
The records of 339 patients, who met inclusion criteria, were included in this study. The results 
are tabulated in Table 1. The results indicate that the majority of the patients (96.8%) were 
diagnosed with malignant neoplasm of the prostate also known as metastatic castrate resistant 
prostate cancer. Patients with ICD 10 codes D07.5, D29.1 and D40.0 were excluded from the 
study. 
 
Table 3.1: Overall population: All ICD 10 Codes: 
ICD 10 
Code 
Description Count of 
MEDRECNO 
Percentage (%) 
C61 Malignant neoplasm of the prostate 328 96.8 
D07.5 Carcinoma in Situ 1 0.3 
D29.1 Benign neoplasm, prostate 1 0.3 
D40.0 Neoplasm of uncertain or unknown 
behaviour, prostate 
9 2.6 
Total  339 100 
 
Of the 328 patients diagnosed with the malignant neoplasm of the prostate, 263 (80%) were not 
treated with Chemotherapy and therefore they were excluded in the study. These results are shown 
in table 3.2. 
 
Table 3.2: Number of patients with ICD 10 code: C61 per race treated and not treated with Chemotherapy. 
Race Asian Black Coloured Other White Grand Total 
Treated 16 39 1 1 8 65 
Not treated 49 160 15 4 35 263 
Grand 
Total 
65 199 16 5 43 328 
Percentage 
(%) 
24.62 60 1.54 1.54 12.31 100 
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Of the C61 ICD 10 Coded patients, 65 (24.62%) were Asian, 199 (60.00%) were black, 16 (1.54%) 
were coloured, 5 (1.54%) were classified as other and 43 (12.31%) were of white race. These 
results indicate that the majority of the patients in this cohort are black and this is consistent with 
the study conducted by Dewar and colleagues (2018) who stated that black men and men with 
West African ancestry are at a higher risk of being diagnosed with PCa. The results are also in line 
with the WHO statistics for PCa and numerous other studies in which black ethnicity is associated 
with a higher risk of PCa diagnosis. 
 
We further categorised patients in the cohort per treatment regimen. The results indicated that 188 
(57.3%), patients were treated with chemotherapy while 42.7% (n=140) were treated with 
Radiotherapy only. The patients who were treated with Radiotherapy only were excluded from the 
study. Of the 57.3% chemotherapy treated patients, 16 (23%) were Asian, 39 were black, 1 were 
coloured and other respectively, while the white race comprised of only 8 patients. 
 
Further analysis of the chemotherapy regimen used per patient showed that of the black population 
in the study only 28 were treated with the chemotherapy as confirmed by MediTech™ records and 
the 11 were excluded because there was no history of the chemotherapy regimen on the records 
and 1 was a child below the age of 3. Of the 16 Asian patients, five were excluded because the 
medical records did not include chemotherapy regimen. The exclusion and inclusion of the patients 
in this cohort is illustrated in Figure 3.1. 
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Figure 3.1: Exclusion and inclusion of patients for the chemotherapy cohort 
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3.2 Nuclear Medicine Cohort 
A total of 26 patient records were reviewed at SBAH (N=26). 11 patients (42.7%) met the inclusion 
criteria and 15 patients (57.7%) were excluded from the study. The reasons for exclusion included 
the following, 47% were of female gender, 20% were treated prior to the study period, 13%, were 
treated with a targeted nuclear medicine regimen other than Lu-PSMA and 13% were not treated 
with any targeted nuclear medicine. Forty five (45%) percent of the included population in the 
cohort were black, and 55% were white. The results indicate that in this population the majority 
of the patients were white, however, this can be attributed to the small size of the cohort and the 
percentage of patients excluded for not meeting the inclusion criteria. Figure 3.2 illustrates the 
percentages of patients that met and those that did not meet the inclusion criteria. The reasons are 
also stated. Other demographic parameters such as age were analysed and compared for the study 
cohorts. 
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Figure 3.2: Population distribution of the Nuclear Medicine Cohort
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3.3 Average Patient-Age at Diagnosis. 
We used descriptive statistics to analyse the age at diagnosis of the two study groups. The results 
indicated that the mean age at diagnosis were 61.2 and 66.3 for the nuclear medicine and 
chemotherapy cohorts respectively. Age at diagnosis is between 41.4 and 80.9 for the nuclear 
medicine cohort and 43.6 and 89.0 for the chemotherapy cohort with standard deviations of 6.6 
and 7.6 respectively. Our data indicates that the age at diagnosis is within the acceptable age range. 
 
Table 3.3: Age at diagnosis for Nuclear Medicine and Chemotherapy cohorts 
 N Minimum Maximum Mean Standard 
Deviation 
(sd) 
Nuclear medicine Cohort age 
at diagnosis 
11 50.0 76.0 61.2 6.6 
Chemotherapy cohort age at 
diagnosis 
49 51.0 81.0 66.3 7.6 
 
 
3.4 Patient Status during the Study 
 
We reviewed the patient’s health status during the study in order determine the overall survival 
during both chemotherapy and Lu-PSMA treatment. Our results indicate that for the nuclear 
medicine cohort, 63.6% of the patients were alive during the study, 27.3% and 9.1% were either  
deceased or lost to follow up respectively.  
 
Table 3.4: Nuclear Medicine cohort patient status 
Patient status Frequency Percentage (%) 
Alive 7 63.6 
Deceased 3 27.3 
Lost to follow up 1 9.1 
Total 11 100 
 
 
We performed a similar frequency analysis for the chemotherapy cohort. 71.4% of the patients 
were alive during the study, 2% and 26.5% were either deceased or lost to follow up respectively. 
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These results indicate that there was a higher percentage of mortality in the nuclear medicine 
cohort. This may be attributed to a smaller population size as well as adequate reporting of the 
mortality to the treatment site. The results also indicate that in both cohorts there was 9.1% and 
26.5% of patients lost to follow up.  
 
Table 3.5 Chemotherapy cohort patient status 
Patient status Frequency Percentage (%) 
Alive 35 71.4 
Deceased 1 2 
Lost to follow up 13 26.5 
Total 49 100 
 
3.5 Gleason score and PSA levels in the Nuclear Medicine Cohort 
 
On presentation at the treatment site, the patient undergoes a number of screening and imaging 
tests. These include PSA screening as well as imaging in order to determine the cancer stage and 
the level of metastasis in the body. The Gleason score is used to aid with the prognosis and the 
PSA is valuable in monitoring and evaluation of biochemical response and recurrence (Gul et al., 
2011). We performed statistical analysis of the PSA and Gleason scores for the Nuclear medicine 
cohort only. There were no data available for the chemotherapy cohort. 
 
Table 3.6: Nuclear medicine cohort Gleason score 
Gleason score Range Frequency Percentage (%) 
>/=6 1 9.1 
7-8 5 45.5 
9+ 1 9.1 
Unknown 4 36.4 
Total 11 100 
 
 
Of the 11 patients with a Gleason score value, our results demonstrate that 9.1% had a Gleason 
score of 9 and 6 respectively. A Gleason score indicates the aggressiveness of the tumour (Gul et 
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al., 2011) and a score of 9 indicates a least- differentiated tumour, with an unfavourable prognosis, 
whilst the Gleason score of 6 according to Parker et al., (2015) indicates a low risk localised 
tumour However, both these patients were still alive during the study. Reference is made to their 
PSA levels and indication of biochemical recurrence with successive PSA screening for the next 
cycles of treatment. 45.5% of the patients had a Gleason score of 7-8, indicating least differentiated 
tumours, and 36.4% of the patient had an unknown Gleason score. This data is in line with the 
findings by Parker et al.,(2015) that a Gleason score of >7 is suggestive of metastatic disease.  The 
chemotherapy cohort Gleason score values were also not indicated. We further evaluated the PSA 
levels of the nuclear medicine cohort. The PSA levels for this cohort were evaluated at the start of 
the treatment and data indicates a mean PSA level of 4.57ng/L. 
 
3.6 Costs 
 
3.6.1 Chemotherapy Cohort 
A total of 11 patients (22.4%) of the cohort were hospitalised, with a mean hospitalisation days of 
13 days, minimum days of hospitalisation being 2 day, and to a maximum of 60 days. Two patients’ 
in-hospitalisation costs (18%) of this sub-population were excluded because the patients were 
hospitalised due to non-cancer related conditions (Cardio-Thoracic surgery and Aortic stenosis 
respectively), however, their OPD related costs were included in the OPD costs. Costs are 
expressed in US Dollars, as per exchange rate as at 06 January 2020, the results are illustrated in 
figure 4.3 below. 
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Figure 3.3: In-patient costs vs out-patient costs for the hospitalised sub-population of the 
chemotherapy cohort. 
 
The results suggest that out-patient costs are higher than in-patient costs, this is consistent with the 
number of days as reflected per visit. An average cost of 25 000$ was incurred for a maximum 90 
days out-patient visits, compared to an in hospital cost of 10 000$ incurred for a maximum of 60 
days. Out-patient days do not include chemotherapy costs. 
 
More than 80% of the patients incurred laboratory costs at an average of 500$, whilst less than 
10% incurred costs at an average cost of between 500-1000$. Less than 5% of the patients incurred 
costs between 1500-2000$ as reflected in figure 4.4. 
59 
 
 
Figure 3.4: Distribution of patients per laboratory costs incurred. 
 
Our results therefor suggests that in this cohort, laboratory costs incurred averaged between a 
minimum of 500$ and a maximum of 2000$. The screening for PSA was also evaluated as part of 
the laboratory costs at IALCH. 
 
Table 3.7: Number of PSA level screening tests for the chemotherapy cohort. 
Number of PSA screening tests Frequency Percentage (%) 
1-10 42 91.3 
10-20 2 4.3 
20-30 1 2.2 
30-40 1 2.2 
Total 46 100.0 
 
 
Our results indicate that 91.3% of the cohort had between 1 and 10 PSA screening tests performed 
during the study. The average cost for PSA screening in this cohort was estimated at 28USD ($) 
for a single test. 4.3% of the cohort had between 10 and 20 PSA tests performed. 2.2% had between 
20 and 30 and 30 and 40 PSA tests respectively. Compared to the nuclear medicine cohort, the 
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chemotherapy cohort had more frequent PSA tests performed. In this cohort, 8% of the patients 
were not screened for PSA level and 22% had one PSA screening. A decline in PSA levels was 
observed in 35% of the patients, whilst an increase (indicative of biochemical recurrence) was 
observed in 33% and only 2% showed a stable (unchanging) PSA level during the study period. 
 
We therefore sought to determine the costs that are incurred for chemotherapy related side effects, 
bone palliation as well as the use of Prednisone during chemotherapy. We performed a detailed 
manual search on MediTech™, for the costs of all regimen used for pain management, bone 
palliation as well as for nausea and vomiting as a common side effect. The results are illustrated 
in Figure 3.5 below. 
 
  
Figure 3.5: Average costs for medication used with Chemotherapy. 
 
 
There were three commonly used chemotherapy regimens for the treatment of PCa. These were, 
docetaxel + bicalutamide + goserelin. Docetaxel was used as monotherapy in 11% of the cohort, 
whilst 34% were treated with a combination of goserelin and bicalutamide. Twenty one (21%) 
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percent of the cohort were treated with goserelin as monotherapy, and 11% with a combination of 
goserelin + bicalutamide + docetaxel. It was also noted that a combination of bicalutamide + 
docetaxel was used in the treatment of 6% of the cohort, whilst cyproterone was administered in 
6% of the cohort. Other combinations accounted for 2% each in the cohort. As result, and as shown 
in Figure 3.7, the costs drivers were found to be docetaxel, goserelin and bicalutamide.  
 
 
 
Figure 3.6: Chemotherapy Regimen 
 
We sourced all chemotherapy related costs from the ABC Facility costs. The results indicate that 
chemotherapy costs have been standardised to an average cost of 454$ (R6462.00) per 
chemotherapy cycle. We computed costs for the cohort, and discovered that 16% of the patients 
were not assigned chemotherapy costs even though the regimen were known.  No costs were 
assigned to these patients as no generalisation on cost allocation could be applied. 
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Figure 3.7: Percentage distribution of chemotherapy costs per treatment cycle. 
 
The number of Chemotherapy treatment cycles received by patients in this cohort ranged from one 
cycle (454US$) to 33 chemotherapy cycles (15003US$). More than 40% of the patients in this 
cohort received one cycle of chemotherapy at an average cost of 454US$. Almost 20% of this 
cohort received 2 chemotherapy cycles at an average cost of 909US$. About 15% of the patients 
received three cycles of chemotherapy averaging 1363US$. Less than 5% of the patients had more 
than 4 cycles of chemotherapy. Two patients had 30 and 33 cycles of chemotherapy at average 
costs of 13 600 and 15 000 US$ respectively.  
 
The administration of chemotherapy was found to be associated with a number of directly related 
costs that ranged from laboratory monitoring costs, specialists costs, radiotherapy costs, imaging 
costs, screening costs as well as the management of complications associated with the disease. We 
computed OPD related costs using data from the ABC costing model and expressed them in US 
Dollars as per exchange rate on 06 January 2020. 
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Figure 3.8: OPD related costs associated with chemotherapy administration. 
 
The OPD costs were not individually analysed per patient, but were bundled up as relevant costs 
that were included in each patient’s visit. These included Urological specialist visits (124$), 
radiotherapy costs from 332$ for example. The costs associated with drawing and analysis of 
chemotherapy bloods were averaged at 504$. The results in Figure 3.8 indicate that the distribution 
of these costs differ from patient to patient, as the level of treatment differs. However, it should be 
noted that these costs in this cohort, were critical in the estimation of the costs associated with 
chemotherapy treatment in this institution. Further analysis of these costs is discussed in the next 
chapter. Once the OPD costs and In-patients costs were analysed, we then presented imaging costs 
for each patient. 
 
Imaging techniques at this institution for the Chemotherapy cohort included Gamma Imaging, PET 
and CT scanning, general X-rays as well as TH Tumour analysis for a patient treated with Lu-
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PSMA in the nuclear medicine unit. We extracted this data from the ABC costing model on 
MediTech™, and the results are shown in Figure 3.9. 
 
 
Figure 3.9: Distribution of Imaging costs 
 
Our data indicates that the mean imaging costs were 993$, with a maximum costs of 5550$. These 
were attributed to a combination of imaging modalities used in this institution. The results suggest 
that imaging costs for the majority of the patients were averaged between 1000$ and 2000$. 
However, some costs escalated to an average of 5550$, which contributed largely to the total 
chemotherapy costs in this cohort. The results also indicated that 18% of the patients in the cohort 
did not have any imaging tests performed.  
 
We then sought to determine the overall costs of chemotherapy treatment in this cohort. The costs 
were extracted from MediTech™ using the ABC Costing model. We converted the total costs and 
presented them in US Dollars.  
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We calculated total costs based on the ABC Facility costing model. The total costs included visits 
(in-patient and out-patient visits), Imaging costs as well as the surgical costs for those patients that 
had been hospitalised due to surgery. It should be noted that surgery costs were not included in 
this study, but in order to be able to compute total costs we included them as they appeared in the 
ABC costing model.  
 
 
 
Figure 3.10: Distribution of Chemotherapy costs for the Chemotherapy Cohort. 
 
The results indicate that the cost drivers in chemotherapy treatment are the number of visits in-
patient and out-patient visits and imaging costs, which accounted for 88% and 8% of the total costs 
respectively.  Costs incurred by patients visiting the hospital included chemotherapy regimen 
costs, direct medical costs such as hospitalisation costs, laboratory costs, specialists costs, costs 
incurred for admission in oncology wards, as well as costs that were incurred for complications of 
the disease. 
 
Surgical costs accounted for 4% of the costs for this cohort. Our results indicate that on average 
healthcare costs incurred for cancer chemotherapy account for almost 500 000$, over a period of 
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3 years. We also noted that medical costs included bone palliation where there has been skeletal 
metastasis, the treatment of side effects as well as supporting regimen such as Prednisone. These 
costs were then compared to the costs incurred when patients are treated with targeted Nuclear 
medicine in a tertiary hospital in Johannesburg, South Africa. 
 
3.6.2 Nuclear Medicine Cohort 
 
In this cohort, records of 11 patients who were treated at the SBAH for metastatic castrate resistant 
PCa, were retrieved and analysed. Each patient was reviewed for PSA screening, Gleason score at 
the beginning of treatment as well as the regimen used. As shown in Figure 3.11, the findings of 
this study indicate that of the 11 patients, 9% of the cohort received 5cycles and a maximum of 6 
cycles of Lutetium treatment respectively. 54.5% of the cohort received 4 treatment cycles of 
Lutetium and 27% received three cycles.  
 
 
 
Figure 3.11: Costs of Lutetium per patient.  
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The majority of patients (55%) incurred an average cost of 16 250$, and 18% of the patients with 
more cycles of Lu-PSMA administered incurred costs above 25 000$. The mean costs of Lu-
PSMA are 16 200$, and a standard deviation of 3634.393. Therefore the costs of Lu-PSMA are 
between 5350$ and 27 100$.  
 
We calculated costs for aminosteryl 8% which was administered with each dose of Lu-PSMA and 
a maximum cost of 450$ was incurred by 27% of the cohort. For each cycle of Lutetium 
administered, the patient or payer incurres a standardised technical cost that covers utility and 
administrative cost. This cost is equivalent to a ward fee that the chemotherapy cohort also 
incurred. We calculated an average cost of 335$ for the recommended 4 Lu-PSMA cycles. These 
costs will be incorporated to the Lu-PSMA costs for the calculation of total costs for the nuclear 
medicine cohort. 
 
Three imaging modalities were used for this cohort, namely Gallium imaging, Renal Imaging as 
well as tumour localisation. Gallium scan is performed per cycle of Lu-PSMA administration. We 
present descriptive statistics in Table 3.8 below for the minimum and maximum costs incurred. 
 
Table 3.8: Imaging Costs for the nuclear medicine cohort: 
 N Minimum Maximum Mean Standard 
Deviation 
(sd) 
Galium – 68 costs 11 1363.0 2726.0 1817.1 406.3 
Tumour localisation 
costs 
11 182.0 364.0 306.1 73.6 
Renal imaging costs 11 91.0 308.0 158.5 82.8 
 
Our data indicates that maximum costs of 2700$, 360$ and 308$ were incurred for Ga-68-PSMA, 
tumour localisation and renal imaging respectively for this cohort. 
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Two weeks prior to the administration of Lu-PSMA, the patient undergoes laboratory testing. We 
performed an analysis of laboratory costs for this cohort and the results suggest that an average 
cost of 450$ was incurred by 55% of this cohort, whilst only 9% incurred costs to the maximum 
of 680$, with a standard deviation of 98.371. Our data therefore suggests that laboratory costs for 
this cohort range between 157$ and 750$. Of the 11 patients reviewed, only 1 patient reported 
xerostomia as a side effect for the nuclear medicine cohort. No treatment costs were allocated for 
this side effect. 
 
We therefore computed total costs for Lutetium treatment for this cohort. We present this data in  
Figure 3.12 
 
 
 
Figure 3.12: Percentage distribution of Lutetium Costs. 
 
The total costs for the treatment of mCRPC for this cohort amounted to 215 380$ for the period of 
study. The cost drivers were found to be Lu-PSMA costs and imaging costs accounting for 83% 
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and 12% of the costs respectively. Laboratory / screening and Technical costs accounted for 2% 
each respectively. The administration of aminosteryl 8% for renal protection accounted for 1% of 
the cost. The results therefore suggest that Lu-PSMA is the cost driver for the costs incurred for 
this cohort amounting to 179 000$. 
 
In order to compare the costs for the treatment of prostate cancer as aimed by this study, we 
compared costs incurred for chemotherapy regimens against the Lutetium costs. The cost 
comparison is illustrated in Figure 3.13. 
 
 
Figure 3.13: Cost comparison for the Nuclear Medicine and Chemotherapy Cohorts. 
 
Our results suggest that the cost of chemotherapy treatment are 58% higher than the cost of nuclear 
medicine. This can be attributed to the differences in population sizes as well as a number of factors 
that need to be explored. The treatment costs in both cohorts include the laboratory / screening 
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costs. In the chemotherapy cohort these include both in-patient and out-patient visits, which may 
account for the difference in costs that is observed.  
 
The imaging costs were observed to be higher for the chemotherapy cohort when compared to the 
nuclear medicine cohort. This difference is estimated to be around 37% of the total costs.  This 
observation may also be attributed to the difference in population size as well as the frequency of 
imaging that each patient in the cohort was exposed to. 
 
3.7 Costs per patient per visit  
 
In order for us to be able to calculate the costs incurred by the patients per visit, we used the total 
costs incurred by the patient at the end of the study and divided them by the total number of visits 
of the patient in each institution, and obtained an average cost per visit for each patient. We then 
performed a one sample t-test for each in order determine if the differences in costs were 
statistically significant, and we obtained the following results illustrated in table… 
 
Table 3. 9 : One sample Tests for Nuclear Medicine and Chemotherapy Cohorts 
Cohort N Mean  Standard 
Deviation 
Std 
Error 
Mean 
t df Sig (2-
tailed) 
Mean 
Difference 
95% Confidence 
interval of difference 
Lower Upper 
Chemo 49 762 1511.26 215.89 0.002 48 0.998 0.48980 -433.5955 434.5751 
Nuclear 
Medicine 
11 4900 47.27 14.25 -0.06 10 0.995 -0.9091 -31.8462 31.6644 
   
The total number of visits for the chemotherapy cohort varied from a single visit to 130 hospital 
visits per patient whilst the nuclear medicine cohort visits varied from 3 to 6 cycles per patient. 
Data from 11 and 49 patients respectively was statistically analysed. 
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3.8 A Rare Case of Prostatic Rhabdomyosarcoma  
 
This patient’s data were analysed separately because of his age, which did not meet the inclusion 
criteria. This male patient, of black race and born on the 22nd January 2015, was diagnosed with 
primary Stage 4 rhabdomyosarcoma. The records showed that he was HIV exposed. First visit at 
the hospital was on 2017/06/05, and between that period and 2018/06/08, patient visited mainly in 
the Paediatric Oncology, Haematology Unit, Paediatric ICU, Paediatric surgery and Paediatric 
High Care. In this hospital, the patient was registered with the ICD 10 code, C61: Malignant 
neoplasm of the prostate.  
 
During this period, the patient had one out-patient visit and 20 in-patient admissions, with a total 
number of in-patient days = 187. No radiotherapy was given, but was treated with chemotherapy 
from 2017/02/22 to 2018/03/26. These visits incurred a total cost of R968 121.22 (68317.22$).  
 
Between 2017/06/05 and 2018/06/08, this patient underwent several procedures in the paediatric 
surgery department, which included prostatectomy, cystectomy, ureterostomy  and two more other 
procedures with a total cost of R112 236 (7920$).  Chemotherapy regimens included vincristine, 
cyclophosphamide, ifosfamide, dactinomycin and doxorubicin. Mesna and filgrastim were 
administered to counteract the side effects of cyclophosphamide and chemotherapy regimen side 
effects respectively. Morphine elixir was used for pain management. The data also shows that 
various antibiotics and other treatment modalities were used during the admission in both 
paediatric surgery wards and paediatric ICU and high care. The costs of these were added to the 
costs of the visit. The total costs for this patient were R 1 097 657.00 (77458.05$). Imaging 
procedures included CT scans of the chest, general X-rays of the abdomen, the right hip and the 
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ultrasound (electrocardiogram) of the thorax to the value of R17300 (1220$).  On the 8th of June 
2018, the patient demised.  
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CHAPTER 4: Discussion, Limitations, Recommendations and Conclusion 
 
4.1 Age at Diagnosis and patient status during the study. 
 
Our results indicated that the mean ages at diagnosis for both cohorts were 61.18 and 66.33 
respectively. Age at diagnosis ranged from 41.4 and 80.9 for the Nuclear Medicine Cohort and 
This data is also supported by the finding by Dewar et al who stated that Black men are diagnosed 
at a younger age and have more severe disease characteristics (Dewar et al, 2018). 
 
For each cohort 9.1% for nuclear medicine and 26.5% of the patients were lost to follow up 
respectively. This suggests that these patients cannot be accounted for as their health status cannot 
be confirmed for this period. This is also made difficult by the fact that South Africa does not have 
a Prostate cancer registry, even though national registries for breast and cervical cancer exist 
(Hayes, et al., 2017). 
 
4.2  The Cost of Treating PCa 
 
This study successfully investigated the costs associated with treating metastatic castrate-resistant 
prostate cancer with standard chemotherapy regimens when compared with the costs incurred for 
metastatic castrate-resistant prostate cancer treatment using targeted nuclear medicine at three 
tertiary hospitals in South Africa. More importantly, this is the first study in SA to compare costs 
of Lu-PSMA to that of chemotherapy regimen costs.  
 
This study indicated that in the chemotherapy cohort, the majority of the patients were Black 
(57%). This is in line with the findings of the study by Dewar et al., (2018) and the WHO statistics, 
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2018 that stated and indicated respectively that Black men are at a higher risk of being diagnosed 
with PCa. Numerous studies both in developed and developing countries have also indicated that 
being male and of African ethnicity predisposes to PCa. 
 
However, it should be noted that in the nuclear medicine cohort, the majority of the patients (55%) 
were white. This may be attributed to the population size. However, it also raises a question that 
was raised by Dewar and colleagues (2018) before, as they espoused that studies focused on SA 
have uniformly found PCa to be more common in white than Black South Africans, and they 
attributed this to lower socio-economic status that an average SA black male might be less likely 
to be screened for PCa, than his other racial counterparts.  
 
Pollard et al.(2016), stated that of men diagnosed with PCa, between 10% -20% will develop 
mCRPC within 5 years of diagnosis after receiving hormone ablation therapy for metastatic disease 
and diagnosis or recurrence. In this study we noted that of the 49 and 11 patients reviewed 
respectively, 6% in the chemotherapy cohort were diagnosed approximately 7 years ago, whilst in 
the nuclear medicine category, the longest diagnosis (9%) dates back to 22 years ago. This is 
noteworthy for this study for two reasons, namely (1),  Lu-PSMA is used as third line therapy, 
when patients do not respond to any third line chemotherapy, and in most cases, this is end-stage 
treatment, which in this case also may account for the high mortality rate observed in this cohort, 
and (2), for the chemotherapy cohort at IALCH, the chemotherapy regimen used, suggests that 
most patients were being treated for palliation of hormone- dependent advanced PCa as well as 
locally advanced prostate cancer in combination with radiotherapy, which accounted for the high 
costs that were incurred in this cohort. 
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The chemotherapy cohort results indicate that the majority of the patients were treated with 
combination therapy as opposed to monotherapy. 11 chemotherapy regimen were observed (figure 
3.6). For cost allocation in this cohort, we identified 22% of the patients in which chemotherapy 
costs were not assigned, even though patients were treated with chemotherapy as evidenced in the 
records, cost calculations could not be performed as the chemotherapy costs were standardised and 
cycles varied from patient to patient.  
 
Gillesen et al., (2018) stated that in mCRPC, there are currently no combination treatment 
strategies for survival-prolonging agents that have shown an overall survival benefit as compared 
with monotherapy. Our study can relate to this statement as observed with the number of 
combination therapies that have been used in this cohort. In this cohort, the cost drivers were found 
to be goserelin, docetaxel and bicalutamide. These drugs were used in monotherapy and/ or in 
combination. 
 
11% and 21% of patients were treated with docetaxel and goserelin monotherapy respectively, 
whilst 34% of patients were treated with bicalutamide and goserelin combination, 11% were 
treated with docetaxel, bicalutamide and goserelin combination and 6% docetaxel and 
bicalutamide combination. Docetaxel, according to De Vita et al., (2015) is approved as the first 
and 3rd line chemotherapy in both symptomatic and asymptomatic PCa patients. It is the only 
pharmaceutical that has shown to have survival benefits (Pollard et al., 2016).  In a study carried 
out by Beebe-Dimer and colleagues (2018) it is stated that lack of consensus exists regarding the 
clinical benefit of bicalutamide use, either alone or in combination with a LHRH like goserelin. 
 
Our study also noted the chronic use of goserelin in this cohort, as it shows that in 21% of the 
patients goserelin was used as monotherapy. Beebe-Dimer et al.,(2018) further state that medical 
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or chemical ADT involves chronic administration of the LHRH agonists or antagonist. The 
findings of this study are consistent with these authors ’statement as the data indicates that in the 
cohort a maximum of 30 cycles of chemotherapy was administered to the value of 13 633$ for one 
patient during the study period. Chemotherapy costs (121 800$) for this cohort accounted for 
29.4% of the out-patient costs. 
 
Bicalutamide is a non-steroidal first generation anti-androgen, FDA approved for use in 
combination therapy with a LHRH analogue, approved for the treatment of stage D2 metastatic 
carcinoma of the prostate (Beebe-Dimer, et al., 2018). It blocks the effects of adrenal androgens 
at the androgen receptor to potentially prevent testosterone flare, hence its widespread use in this 
cohort. None of the recently FDA approved chemotherapy regimens such as arbiraterone, 
enzalutamide and cabazitaxel were used in this cohort. 
 
The utility costs included costs for radiotherapy, urology specialist, radiology, haematology, 
oncology/ chemo bloods, treatment of oncological complications, general urology and oncology 
visits. These costs were deemed direct costs as they contributed to the holistic healthcare approach 
for the patient. This accounted (292 682$) for 70.4% of the out-patient costs.  
 
 Both docetaxel and Lu-PSMA are indicated for the treatment of mCRPC (De Vita et al., 2015;  
Von Eyben et al., 2017). In the nuclear medicine cohort, lutetium costs accounted for 83% of the 
total costs (178 796$). If chemotherapy costs are separated from the utility costs they account for 
121 800$, and when compared to lutetium costs (178 796$), the lutetium costs are 1.5 times the 
costs of chemotherapy. Lutetium according to Von Eyben et al.,(2017) is associated with a PSA 
decline of more than 50%. In the nuclear medicine cohort, a decline in PSA of between 23% and 
51% was observed in 36.4% of the cohort. Biochemical recurrence was also observed in 36.4% of 
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the patients, no further analysis was performed in 27.3% of the cohort. PSA screening costs were 
incorporated into the lab costs (4975$) and accounted for 1.3% of the total lutetium costs. 
 
The total costs of imaging were 25 098$ and 39 809$ for the nuclear medicine and chemotherapy 
cohorts respectively. The costs incurred for imaging the chemotherapy cohort were 61% higher 
than the costs for the nuclear medicine cohort. Ga-68-PSMA PET/CT scan was used for the nuclear 
medicine cohort, together with the renal scan and the tumour localising imaging. The low costs 
associated with this cohort may be due to the size of the population and may not reflect the actual 
costs that may be incurred if the size of the population increased. 
 
The higher costs associated with the chemotherapy imaging may also be attributed to a larger 
population size for this cohort. In this cohort a variety of imaging procedures were utilised at 
IALCH, due to the diverse nature of the patients. Several imaging scans were used which included 
the Gamma camera, CT planning scanning, PET scans, General X-Rays as well as TH tumour 
localising scans for nuclear medicine. Of noteworthy in this context, was the individual costs of 
the Ga-68-PET/CT Scan (452$), compared to a Gamma scan (664$) per cycle. This difference in 
costs may have contributed to the high costs incurred for the chemotherapy cohort. We needed to 
identify if the differences in these costs were statistically significant. 
 
The treatment costs were found to be 183 771$ and 435 717$ for the nuclear medicine and the 
chemotherapy cohorts respectively. The costs of treating the chemotherapy cohort were found to 
be 2.4 times higher than the nuclear medicine cohort. A number of plausible contributing factors 
were identified. In the nuclear medicine cohort, the total treatment costs were driven by the cost 
of the Lutetium itself (83% of the total costs), no hospitalisation costs were reported to be incurred 
by this cohort compared to the chemotherapy cohort where in-patient costs, out-patient costs, and 
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direct chemotherapy were incurred. Laboratory/screening costs also had a direct contribution to 
the escalation of treatment costs for the chemotherapy cohort.  
Our findings also indicated that the costs for a single visit for Chemotherapy range significantly 
wide, from a minimum of $12 to a maximum of $9096, whereas the costs for a single visit for 
nuclear medicine have a much narrower range (a uniform distribution) from a minimum of $4826 
to a maximum of $4926 for the two  cohorts when compared. The data showed that nuclear 
medicine costs approach uniformity and better predictability compared to chemotherapy costs. 
 
Our data also indicated that the standard deviation in costs for chemotherapy is quite big ($1511) 
compared to a very small standard deviation ($47) in nuclear medicine treatment. These 
differences are statistically significant for a patient who will need to plan their therapy upfront in 
order to be able to complete their cycles without running into financial challenges in the middle of 
the treatment regimen. 
 
We sought to investigate if there were monetary and overall survival benefits in treating prostate 
cancer with chemotherapy regimen compared to nuclear medicine regimen. From the results 
obtained, in a cohort of 49 patients in chemotherapy cohort, one death was reported, which is 
suggestive of a low mortality rate in this cohort. However, 20.4% in this cohort were lost to follow 
up. The causes could not be determined as no reasons were stipulated in the records, neither is 
there an existence of a prostate cancer registry in SA where such deaths if there were, could be 
confirmed. 77.6% of the patients were still alive. From an observational point, the survival rate in 
this cohort is stable. From the perspective of costs, it was evidenced by the high costs in incurred 
by this cohort in imaging costs, out-patient and in-patient costs, and laboratory costs that health 
benefits outweigh monetary benefits in this cohort. 
 
In the nuclear medicine cohort, 27.3% were deceased, 9.1% lost to follow up and 63.6% alive. The 
mortality rate in this cohort is higher than in the chemotherapy cohort. This may be attributed to 
the fact that patients who were treated in this treatment centre, some were no longer responsive to 
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third line chemotherapy, biochemical recurrence was also observed that was suggestive of end 
stage disease. No decisive overall survival could be determined based on the small size of the 
population and that to the author’s knowledge, this is the first cost comparison study where 
lutetium is compared to standard chemotherapy, therefore no model could be created or referenced 
to calculate the overall survival, except to compare the percentages of patients still alive at the end 
of the study. The results indicate that 63.6% of the cohort were still alive at the end of this study, 
and therefore, from the observational point, overall survival is stable for this cohort.  
 
We also sought to investigate if there was any biochemical recurrence observed with monitoring 
of the PSA levels during the treatment of the patients with each regimen type.  
 
PSA levels were monitored for the Nuclear Medicine cohort and it was observed that in 27.3% of 
the patients, only one PSA level was obtained and no further analysis for these patients was 
conducted. In 36.4% it was noted that there was biochemical recurrence with fluctuations in PSA 
levels during the treatment cycles. PSA level declines in the range of 23-51% were observed in 
36.4% of the cohort. This result is consistent with the findings of Von Eyben and colleagues (2017) 
where PSA levels with the treatment of Lu-PSMA were observed to decline up to a level </=50%. 
This might be a plausible explanation as to the overall survival that has been observed in the 
nuclear medicine cohort. 
 
Biochemical recurrence was observed in 33% of the chemotherapy cohort, whilst 35% of the 
cohort showed a decline in the PSA levels. Only 2% of the cohort had an unchanged PSA level 
during the study. 8% of the cohort did not have PSA monitoring or screening, and 22% had a single 
screening test for PSA levels. Our results indicated that for the majority of the patients, the 
treatment modalities used, caused a decline in the PSA levels, which was indicative of disease 
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improvement, whilst in 33% disease progression was observed. For all patients treated, costs were 
incurred, we also focused on the payment modalities and who incurred the costs.  
 
South Africa has a two-tiered healthcare system where the majority of the population relies on the 
government for healthcare services. In this study, our results indicated that for the chemotherapy 
cohort, 90% of the patients were classified as H0 (non-paying patients), 6% were classified as H1, 
2% were classified as H2 and H3 respectively. However, in the nuclear medicine cohort, the 
majority of patients (64%) were classified as PH which meant that they were either paying out of 
pocket (14% of the 64%), or medical aid funded (50% of the 64%). 27% and 9% of the nuclear 
medicine cohort were classified as H0 and H2 respectively. 
 
Our findings therefore suggests that the majority of the patients are state funded for the 
chemotherapy cohort, whilst in the nuclear medicine cohort the patients or the healthcare funder 
incurs the majority of the costs. These findings are consistent with the findings of Addae-Korankye 
(2013) who reported that the ability of the national governments to provide funding for healthcare 
and to sustain the funding is a huge responsibility. In this case, South Africa is no exception, as 
our findings suggest that the burden of Prostate cancer in public hospitals lies with the national 
department of health to fund the hospitalisation, imaging, laboratory and treatment costs for the 
majority of patients with Metastatic castration resistant prostate cancer. Medical aids play a crucial 
role in addressing the financial burden of this disease, however, it is only a minority of the 
population studied as this study indicates, that are covered by the medical aid and therefore are 
able to access nuclear medicine treatment.  
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Future research is needed to evaluate such disparities, costs incurred for the treatment of prostate 
cancer by medical insurers, patients and the national government to assist decision makers and 
policy makers. 
 
4.3 Limitations of this Study 
 
The following limitations were observed for this study: 
● Gleason score values were not available from MediTech™, for accurate staging of the 
patients in the chemotherapy cohort. 
● Missing data points were observed for the 11% of the chemotherapy cohort for 
chemotherapy costs. This impacted on the presentation of the total costs of chemotherapy 
for this cohort. 
● The unavailability of dexamethasone and ondansetron costs for the nuclear medicine 
cohort, impacted on the presentation of the overall costs for this cohort. We also note that 
the administration of Lu-PSMA is accomplished by ensuring that there is hepatic protection 
during the administration, supportive care in the form of a cortisone administration as well 
as antiemetic regimen. The data obtained did not provide costs for the antiemetic and 
cortisone, and these were not be included in this study. However, it should be noted that 
Dexamethasone injection and Ondansetron were intravenously administered with each 
dose of Lutetium. 
● Our study could not effectively address the duration of treatment as treatment costs were 
presented as part of the total visits, and the study design did not accommodate the 
determination of treatment duration. 
● The researcher could not have direct access to the MediTech™ system to access clinical 
records as the system is managed by the IT department at IALCH and authorisation could 
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not be obtained. PSA records also could be accessed, but it could not be determined when 
treatment modalities were adjusted for patients with biochemical recurrence. 
●  A small sample size was obtained at SBAH and the results could not be generalised to the 
SA population. 
4.4 Recommendations  
 
The following are the recommendations of this study for the improvement of clinical practice at 
the SBAH, Nuclear Medicine Department; 
- medical personnel conduct a random audit of patient files in order to ensure accurate data 
management. 
- records of information on all the charges of tests including drugs that are used for the 
administration of lutetium such as dexamethasone and ondansetron, be kept in order for 
the costs to be readily available to researchers and to enhance clinical practice and 
judgement. 
 
At IALCH; 
- continuous improvement of the MediTech™ system, and training of personnel to ensure 
that data integrity is preserved, and errors are timeously corrected in order to ensure that 
no data is missing, recommended. 
Further studies on prostate cancer costs and clinical evaluation such as combination therapies used 
and the rationale behind such therapies need to be conducted for a better understanding of the 
treatment modalities used in this hospital. 
 
It is also recommended that a PCa registry be created for SA to ensure that there is traceability of 
patients diagnosed with PCa. 
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4.5 Conclusion 
 
In conclusion, the findings of this study suggest that for the treatment of metastatic resistant 
prostate cancer, this study indicates that patients treated with chemotherapy is more costly as 
compare to targeted nuclear medicine. However, a larger survey or audit research is needed to 
confirm the findings of this study. 
 
4.6  Disclosure 
 
Nomaswazi Gabela, is an employee of NTP-Radioisotopes. This tuition fees for this study were 
funded by NTP – Radioisotopes, the manufacturers of Lu-177-n.c.a. However, NTP Radio-
isotopes did not contribute in the data analysis and the compilation of the research findings. The 
author is responsible for this work. 
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